<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='/w/ProjectMundo-Anon-106A/style/jats-html.xsl'?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-023-44432-3
   </article-id>
   <article-id pub-id-type="manuscript">
    44432
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-023-44432-3
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/255/2514
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/1807/1486
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/443/319/320
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/443/319/333/1465
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/1647/245/2225
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /14/63
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /14/1
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /82/58
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /13/51
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /96/34
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Matatizo ya misuli yanazidi kuwa mabaya baada ya uchovu wa baada ya mazoezi katika COVID ndefu
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4560-8410
     </contrib-id>
     <name name-style="western">
      <surname>
       Appelman
      </surname>
      <given-names>
       Brent
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4242-3664
     </contrib-id>
     <name name-style="western">
      <surname>
       Charlton
      </surname>
      <given-names>
       Braeden T.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Goulding
      </surname>
      <given-names>
       Richie P.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4046-2504
     </contrib-id>
     <name name-style="western">
      <surname>
       Kerkhoff
      </surname>
      <given-names>
       Tom J.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0009-0006-2516-0694
     </contrib-id>
     <name name-style="western">
      <surname>
       Breedveld
      </surname>
      <given-names>
       Ellen A.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Noort
      </surname>
      <given-names>
       Wendy
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Offringa
      </surname>
      <given-names>
       Carla
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Bloemers
      </surname>
      <given-names>
       Frank W.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4916-2866
     </contrib-id>
     <name name-style="western">
      <surname>
       van Weeghel
      </surname>
      <given-names>
       Michel
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <name name-style="western">
      <surname>
       Schomakers
      </surname>
      <given-names>
       Bauke V.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Coelho
      </surname>
      <given-names>
       Pedro
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff9">
      9
     </xref>
     <xref ref-type="aff" rid="Aff10">
      10
     </xref>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Posthuma
      </surname>
      <given-names>
       Jelle J.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff12">
      12
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-3542-3770
     </contrib-id>
     <name name-style="western">
      <surname>
       Aronica
      </surname>
      <given-names>
       Eleonora
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff11">
      11
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-2277-1343
     </contrib-id>
     <name name-style="western">
      <surname>
       Joost Wiersinga
      </surname>
      <given-names>
       W.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff13">
      13
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="Au15">
     <name name-style="western">
      <surname>
       van Vugt
      </surname>
      <given-names>
       Michèle
      </given-names>
     </name>
     <address>
      <email>
       m.vanvugt@amsterdamumc.nl
      </email>
     </address>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff14">
      14
     </xref>
     <xref ref-type="corresp" rid="IDs41467023444323_cor15">
      r
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="Au16">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-3781-5177
     </contrib-id>
     <name name-style="western">
      <surname>
       Wüst
      </surname>
      <given-names>
       Rob C. I.
      </given-names>
     </name>
     <address>
      <email>
       r.wust@vu.nl
      </email>
     </address>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="corresp" rid="IDs41467023444323_cor16">
      s
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05grdyy37
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.509540.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 6880 3010
      </institution-id>
      <institution content-type="org-division">
       Amsterdam UMC location University of Amsterdam
      </institution>
      <institution content-type="org-name">
       Center for Experimental and Molecular Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Meibergdreef 9
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution content-type="org-division">
       Amsterdam Institute for Infection and Immunity
      </institution>
      <institution content-type="org-name">
       Infectious diseases
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/008xxew50
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.12380.38
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1754 9227
      </institution-id>
      <institution content-type="org-division">
       Department of Human Movement Sciences, Faculty of Behavioral and Movement Sciences
      </institution>
      <institution content-type="org-name">
       Vrije Universiteit Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Amsterdam Movement Sciences
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/008xxew50
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.12380.38
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1754 9227
      </institution-id>
      <institution content-type="org-division">
       Department of Physiology
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC location Vrije Universiteit Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      De Boelelaan 1117
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Amsterdam Cardiovascular Sciences
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04dkp9463
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7177.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000000084992262
      </institution-id>
      <institution content-type="org-division">
       Department of Trauma Surgery
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC location University of Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Meibergdreef 9
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04dkp9463
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7177.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0000 8499 2262
      </institution-id>
      <institution content-type="org-division">
       Laboratory Genetic Metabolic Diseases, Core Facility Metabolomics
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC location University of Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Meibergdreef 9
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff9">
     <label>
      9
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05bz1tw26
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.411265.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2295 9747
      </institution-id>
      <institution content-type="org-division">
       Serviço de Neurologia, Departamento de Neurociências e Saúde Mental
      </institution>
      <institution content-type="org-name">
       Hospital de Santa Maria, CHULN
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Lisbon
     </addr-line>
     <country country="PT">
      Portugal
     </country>
    </aff>
    <aff id="Aff10">
     <label>
      10
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01c27hj86
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.9983.b
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2181 4263
      </institution-id>
      <institution content-type="org-division">
       Faculdade de Medicina, Centro de Estudos Egas Moniz
      </institution>
      <institution content-type="org-name">
       University of Lisbon
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Lisbon
     </addr-line>
     <country country="PT">
      Portugal
     </country>
    </aff>
    <aff id="Aff11">
     <label>
      11
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04dkp9463
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7177.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000000084992262
      </institution-id>
      <institution content-type="org-division">
       Department of (Neuro)pathology, Amsterdam Neuroscience
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC location University of Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Meibergdreef 9
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff12">
     <label>
      12
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02tqqrq23
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.440159.d
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0497 5219
      </institution-id>
      <institution content-type="org-name">
       Flevoziekenhuis, Division of Surgery
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Hospitaalweg 1
     </addr-line>
     <addr-line content-type="city">
      Almere
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff13">
     <label>
      13
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04dkp9463
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7177.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000000084992262
      </institution-id>
      <institution content-type="org-division">
       Division of Infectious Diseases, Department of Internal Medicine
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC location University of Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Meibergdreef 9
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
    <aff id="Aff14">
     <label>
      14
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/04dkp9463
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.7177.6
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000000084992262
      </institution-id>
      <institution content-type="org-division">
       Division of Infectious Diseases, Tropical Medicine, Department of Medicine
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC location University of Amsterdam
      </institution>
     </institution-wrap>
     <addr-line content-type="street">
      Meibergdreef 9
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      the Netherlands
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Brent Appelman, Braeden T. Charlton, Michèle van Vugt, Rob C. I. Wüst.
     </p>
    </fn>
    <corresp id="IDs41467023444323_cor15">
     <label>
      r
     </label>
     <email>
      m.vanvugt@amsterdamumc.nl
     </email>
    </corresp>
    <corresp id="IDs41467023444323_cor16">
     <label>
      s
     </label>
     <email>
      r.wust@vu.nl
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     4
    </day>
    <month>
     1
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="17">
    1
   </issue>
   <elocation-id>
    17
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      13
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      21
     </day>
     <month>
      3
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      13
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      4
     </day>
     <month>
      1
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <related-article ext-link-type="doi" related-article-type="article-reference" xlink:href="10.1038/s41467-025-56427-3"/>
   <related-article ext-link-type="doi" related-article-type="companion" xlink:href="10.1038/s41467-025-56428-2"/>
   <related-article ext-link-type="doi" related-article-type="article-reference" xlink:href="10.1038/s41467-025-56430-8"/>
   <related-article ext-link-type="doi" related-article-type="companion" xlink:href="10.1038/s41467-025-56431-7"/>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Muhtasari
    </title>
    <p id="Par1">
     Kikundi kidogo cha wagonjwa walioambukizwa na SARS-CoV-2 hubaki na dalili zaidi ya miezi mitatu baada ya maambukizi. Dalili ya kipekee ya wagonjwa wenye COVID ndefu ni uchovu wa baada ya mazoezi, ambao unahusishwa na kuzorota kwa dalili zinazohusiana na uchovu na maumivu baada ya mazoezi makali ya akili au mwili, lakini pathofiziolojia yake ya msingi haijulikani. Kwa utafiti huu wa muda mrefu wa kesi-kudhibiti (NCT05225688), tunatoa maarifa mapya katika pathofiziolojia ya uchovu wa baada ya mazoezi kwa wagonjwa wenye COVID ndefu. Tunaonyesha kuwa muundo wa misuli ya mifupa unahusishwa na uwezo mdogo wa mazoezi kwa wagonjwa, na usumbufu wa kimetaboliki wa ndani na wa mfumo mzima, myopathy kali inayosababishwa na mazoezi na kuingizwa kwa tishu za amiloidi katika misuli ya mifupa ya wagonjwa wenye COVID ndefu kunazidi kuwa mbaya baada ya uchovu wa baada ya mazoezi. Utafiti huu unaangazia njia mpya zinazosaidia kuelewa pathofiziolojia ya uchovu wa baada ya mazoezi kwa wagonjwa wanaougua COVID ndefu na magonjwa mengine ya baada ya maambukizi.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     In this longitudinal, case-controlled, cohort design study, authors show that post-exertional malaise is associated with severe exercise-induced myopathy, local and systemic metabolic disturbances and infiltration of amyloid-containing deposits in skeletal muscles of patients with long COVID.
    </p>
   </abstract>
   <kwd-group kwd-group-type="publisher-auto-generated" vocab="springer-nature-taxonomy" xml:lang="en">
    <kwd>
     Neuromuscular disease
    </kwd>
    <kwd>
     Adverse effects
    </kwd>
    <kwd>
     Musculoskeletal abnormalities
    </kwd>
    <kwd>
     SARS Virus
    </kwd>
    <kwd>
     Metabolic syndrome
    </kwd>
    <kwd>
     COVID19
    </kwd>
   </kwd-group>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1103">
      Clinical Sciences
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        ZonMw (Netherlands Organisation for Health Research and Development)
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        https://doi.org/10.13039/501100001826
       </institution-id>
      </institution-wrap>
     </funding-source>
    </award-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        the Patient-Led Research Collaborative for Long COVID the Talud Foundation for the Amsterdam UMC Corona Research Fund AMC Foundation VU Foundation ZonMw Onderzoeksprogramma ME/CVS 2022 Ramsay Grant Program
       </institution>
      </institution-wrap>
     </funding-source>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      10926
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      12
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      13
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2023_Article_44432.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-online-date-year
     </meta-name>
     <meta-value>
      2025
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-online-date-month
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-online-date-day
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      discipline
     </meta-name>
     <meta-value>
      Humanities and Social Sciences
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Utangulizi
   </title>
   <p id="Par3">
    Madhara ya muda mrefu baada ya maambukizi makali huchangia hali zinazodhoofisha ambazo huathiri mamilioni duniani kote
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Baada ya maambukizi makali ya SARS-CoV-2, kundi la wagonjwa hupata madhara ya baada ya COVID-19 (PASC), pia huitwa long COVID
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    . Dalili zinazotajwa zaidi za long COVID ni pamoja na uvumilivu mdogo wa mazoezi na uchovu baada ya mazoezi, unaoashiria kuzorota kwa dalili baada ya juhudi za kiakili au kimwili
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    . Nadharia za sasa, ingawa hazijathibitishwa, zinazojaribu kuelezea uvumilivu wa mazoezi na uchovu baada ya mazoezi katika long COVID ni pamoja na kutofanya kazi vizuri kwa mitochondria, mkusanyiko wa amiloidi katika mishipa ya damu unaosababisha hypoxia ya ndani, uvimbe wa kimfumo na wa ndani, majibu ya kinga yaliyovurugika, usawa wa homoni, na uwepo wa virusi
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     ,
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     ,
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    . Kiwango ambacho fiziolojia ya msingi ya uwezo wa mazoezi ulioharibika inaweza kutenganishwa na mambo yanayohusiana na mwanzo wa uchovu baada ya mazoezi bado haijafahamika, hasa kutokana na tathmini isiyo ya moja kwa moja ya vigezo vya kibiolojia na kisaikolojia, asili ya msalaba ya tafiti nyingi, na utofauti wa wagonjwa.
   </p>
   <p id="Par4">
    Katika utafiti huu, tulisababisha uchovu baada ya mazoezi kwa utaratibu katika kundi la wagonjwa 25 waliobainishwa vizuri wenye long COVID na udhibiti. Tulipata sampuli za damu na biopsi za misuli ya mifupa kabla na baada ya mtihani wa mazoezi ya juu (Supplemental Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     1
    </xref>
    ) kwa lengo la kusoma mambo ya kibayolojia yanayochangia uwezo mdogo wa mazoezi na uchovu baada ya mazoezi katika long COVID. Matokeo yalilinganishwa na yale yaliyopatikana kutoka kwa udhibiti 21 waliolingana kwa umri na jinsia ambao walipona kabisa kutoka kwa maambukizi ya SARS-CoV-2 ya kiwango cha chini (Table
    <xref ref-type="table" rid="Tab1">
     1
    </xref>
    ). Tulibainisha Long COVID kulingana na vigezo vilivyowekwa na Shirika la Afya Duniani, na kigezo muhimu cha kujumuisha kilikuwa uwepo wa uchovu baada ya mazoezi
    <sup>
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
    </sup>
    . Vikundi vyote viwili vilikuwa na afya na vilikuwa na shughuli za kijamii kabla ya maambukizi ya awali ya SARS-CoV-2 yaliyothibitishwa na PCR. Hakuna mshiriki aliyelazwa hospitalini kutokana na maambukizi ya SARS-CoV-2. Maswali ya uchovu na data za accelerometer zilithibitisha athari za long COVID katika maisha ya kila siku (Supplemental Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     2
    </xref>
    ). Tunaonyesha kuwa muundo wa misuli ya mifupa unahusishwa na uwezo mdogo wa mazoezi kwa wagonjwa na kwamba usumbufu wa kimetaboliki wa ndani na wa kimfumo, myopathy kali inayosababishwa na mazoezi na kuingizwa kwa tishu za amiloidi katika misuli ya mifupa ya wagonjwa wenye long COVID huzidi kuwa mbaya baada ya kusababisha uchovu baada ya mazoezi.
    <table-wrap id="Tab1">
     <label>
      Jedwali 1
     </label>
     <caption xml:lang="sw">
      <p>
       Sifa za washiriki
      </p>
     </caption>
     <table frame="hsides" rules="groups">
      <thead>
       <tr>
        <th/>
        <th>
         <p>
          Udhibiti wa afya
         </p>
        </th>
        <th>
         <p>
          COVID ndefu
         </p>
        </th>
        <th>
         <p>
          <italic>
           p
          </italic>
          -thamani
         </p>
        </th>
       </tr>
      </thead>
      <tbody>
       <tr>
        <td>
         <p>
          Idadi ya washiriki
         </p>
        </td>
        <td>
         <p>
          21
         </p>
        </td>
        <td>
         <p>
          25
         </p>
        </td>
        <td/>
       </tr>
       <tr>
        <td colspan="4">
         <p>
          <italic>
           Demografia
          </italic>
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Umri, wastani (SD), miaka
         </p>
        </td>
        <td>
         <p>
          42 (10)
         </p>
        </td>
        <td>
         <p>
          41 (11)
         </p>
        </td>
        <td>
         <p>
          0.82
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Jinsia, wanaume (%)
         </p>
        </td>
        <td>
         <p>
          10 (47.6)
         </p>
        </td>
        <td>
         <p>
          12 (48.0)
         </p>
        </td>
        <td>
         <p>
          &gt;0.99
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          BMI, wastani (SD), kg/m
          <sup>
           2
          </sup>
         </p>
        </td>
        <td>
         <p>
          24.14 (3.37)
         </p>
        </td>
        <td>
         <p>
          25.60 (4.62)
         </p>
        </td>
        <td>
         <p>
          0.24
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Kielezo cha Magonjwa ya Msingi cha Charlson, wastani [IQR]
         </p>
        </td>
        <td>
         <p>
          0 [0, 0]
         </p>
        </td>
        <td>
         <p>
          0 [0, 1]
         </p>
        </td>
        <td>
         <p>
          0.76
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Kulazwa hospitalini kwa COVID-19
         </p>
        </td>
        <td>
         <p>
          0 (0)
         </p>
        </td>
        <td>
         <p>
          (0)
         </p>
        </td>
        <td>
         <p>
          &gt;0.99
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Chanjo ya SARS-CoV-2 kabla ya kushiriki (%)
         </p>
        </td>
        <td>
         <p>
          21 (100)
         </p>
        </td>
        <td>
         <p>
          24 (96.0)
         </p>
        </td>
        <td>
         <p>
          &gt;0.99
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Saa za kazi kwa wiki kabla ya maambukizi ya awali ya SARS-CoV-2, wastani [IQR]
         </p>
        </td>
        <td>
         <p>
          36 [32, 40]
         </p>
        </td>
        <td>
         <p>
          36 [32, 45]
         </p>
        </td>
        <td>
         <p>
          0.520
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Saa za kazi kwa wiki wakati wa utafiti, wastani [IQR]
         </p>
        </td>
        <td>
         <p>
          36 [32, 40]
         </p>
        </td>
        <td>
         <p>
          5 [0, 12]
         </p>
        </td>
        <td>
         <p>
          &lt;0.001
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Muda tangu maambukizi ya awali ya SARS-CoV-2, wastani [IQR], siku
         </p>
        </td>
        <td>
         <p>
          142 [105, 405]
         </p>
        </td>
        <td>
         <p>
          545 [455, 686]
         </p>
        </td>
        <td>
         <p>
          0.001
         </p>
        </td>
       </tr>
       <tr>
        <td>
         <p>
          Muda tangu maambukizi ya hivi karibuni ya SARS-CoV-2, wastani [IQR], siku
         </p>
        </td>
        <td>
         <p>
          135 [93, 197]
         </p>
        </td>
        <td>
         <p>
          504 [329, 665]
         </p>
        </td>
        <td>
         <p>
          0.002
         </p>
        </td>
       </tr>
      </tbody>
     </table>
     <table-wrap-foot>
      <p>
       Takwimu za parametric endelevu zilichambuliwa kwa kutumia mtihani wa
       <italic>
        t
       </italic>
       wa pande mbili na zinaonyeshwa kama wastani na SD. Takwimu zisizo za parametric endelevu zilichambuliwa kwa kutumia mtihani wa Wilcoxon wa pande mbili na zinaonyeshwa kama wastani na safu ya kati. Thamani za
       <italic>
        p
       </italic>
       hazikurekebishwa kwa majaribio mengi. Data ya chanzo imetolewa katika Faili ya Data ya Chanzo.
      </p>
     </table-wrap-foot>
    </table-wrap>
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Uwezo mdogo wa mazoezi katika long COVID
    </title>
    <p id="Par5">
     Washiriki wote walifanya mtihani wa mazoezi ya moyo na mapafu kwenye ergometer ya baiskeli. Uingizaji wa oksijeni wa juu zaidi (V̇O
     <sub>
      2max
     </sub>
     ) na pato la nguvu ya kilele vilikuwa vya chini sana kwa wagonjwa wa long COVID (Fig.
     <xref ref-type="fig" rid="Fig1">
      1A, B
     </xref>
     ), licha ya utofauti mkubwa kati ya wagonjwa. Wagonjwa wenye long COVID walikuwa na uingizaji hewa wa juu zaidi na shinikizo la sehemu ya mwisho ya CO
     <sub>
      2
     </sub>
     (PETCO
     <sub>
      2
     </sub>
     ) lililokuwa chini zaidi, ikimaanisha kazi duni ya upumuaji wakati wa mazoezi (Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      3A–C
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
     </sup>
     . Mfumo wa moyo na mishipa haukuathirika kwa wagonjwa wa long COVID (Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      3D, E
     </xref>
     ), ikimaanisha kuwa mfumo huu hauwezi kuelezea uwezo mdogo wa mazoezi kwa wagonjwa wenye long COVID. Pigo la juu zaidi la O
     <sub>
      2
     </sub>
     (yaani, bidhaa ya ujazo wa pigo na tofauti ya arteriovenous O
     <sub>
      2
     </sub>
     ; Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      3F
     </xref>
     ), kizingiti cha kubadilishana gesi (Fig.
     <xref ref-type="fig" rid="Fig1">
      1C
     </xref>
     ), na uchimbaji wa O
     <sub>
      2
     </sub>
     wa pembeni (uliobainishwa kupitia spectroscopy ya karibu-infrared; Fig.
     <xref ref-type="fig" rid="Fig1">
      1D, E
     </xref>
     , Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      3I
     </xref>
     ) wakati wa mazoezi yote yalionyesha uharibifu wa misuli ya mifupa ya pembeni kwa wagonjwa. V̇O
     <sub>
      2max
     </sub>
     ya chini kwa wagonjwa haikutokana na juhudi ndogo wakati wa mtihani wa mazoezi, kwani uwiano wa washiriki wanaofikia plateau katika V̇O
     <sub>
      2
     </sub>
     haukutofautiana kati ya vikundi, kizingiti cha kubadilishana gesi kilikuwa katika asilimia sawa za V̇O
     <sub>
      2max
     </sub>
     , na vigezo vya sekondari ([lactate], RER ya juu zaidi na kiwango cha moyo) vilifikiwa katika vikundi vyote viwili (Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      3E, G, H
     </xref>
     ).
     <fig id="Fig1" position="float">
      <label>
       Fig. 1
      </label>
      <caption xml:lang="en">
       <title>
        Uwezo wa chini wa mazoezi kwa wagonjwa wenye long COVID.
       </title>
       <p>
        Uchukuaji wa oksijeni ya mapafu ya juu zaidi (V̇O
        <sub>
         2max
        </sub>
        ,
        <bold>
         A
        </bold>
        ,
        <italic>
         n
        </italic>
        = 23 long COVID,
        <italic>
         n
        </italic>
        = 21 udhibiti wenye afya), pato la nguvu ya kilele (
        <bold>
         B
        </bold>
        ,
        <italic>
         n
        </italic>
        = 25 long COVID,
        <italic>
         n
        </italic>
        = 21 udhibiti wenye afya) na kizingiti cha kubadilishana gesi (
        <bold>
         C
        </bold>
        ,
        <italic>
         n
        </italic>
        = 23 long COVID,
        <italic>
         n
        </italic>
        = 21 udhibiti wenye afya) vilikuwa vya chini (
        <italic>
         p
        </italic>
        &lt; 0.0001,
        <italic>
         p
        </italic>
        = 0.001 na
        <italic>
         p
        </italic>
        = 0.014, mtawalia) kwa wagonjwa wenye long COVID ikilinganishwa na udhibiti wenye afya.
        <bold>
         D
        </bold>
        na
        <bold>
         E
        </bold>
        Majibu ya misuli isiyo na oksijeni [heme] (wastani ± SD) yaliyopimwa kwa kutumia spectroscopy ya karibu-infrared yalikuwa ya chini (
        <italic>
         p
        </italic>
        = 0.023) kwa long COVID (
        <italic>
         n
        </italic>
        = 16), ikionyesha uchimbaji wa chini wa oksijeni ya pembeni wakati wa mazoezi ikilinganishwa na udhibiti wenye afya (
        <italic>
         n
        </italic>
        = 18; tishu nyingi za mafuta zilizuia uchambuzi wa data kwa washiriki waliobaki). Data za parametric endelevu zilichambuliwa kwa kutumia mtihani wa
        <italic>
         t
        </italic>
        wa pande mbili (picha
        <bold>
         A–C
        </bold>
        ). Data za parametric za muda mrefu (wastani ± SD; picha
        <bold>
         D
        </bold>
        na
        <bold>
         E
        </bold>
        ) zilichambuliwa kwa kutumia mfano wa mchanganyiko wa mstari wa jumla. Thamani za
        <italic>
         p
        </italic>
        kwa picha
        <bold>
         D
        </bold>
        ,
        <bold>
         E
        </bold>
        zilidhamiriwa kwa mtihani wa ANOVA wa pande mbili. Mstari uliokatika (
        <bold>
         D
        </bold>
        ) unawakilisha wastani wa mwanzo wa mtihani wa mazoezi. *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.001. Mchoro wa sanduku unaonyesha wastani (mstari wa katikati), robo ya kwanza na ya tatu (mipaka ya chini na ya juu ya sanduku), na whiskers zinaonyesha 1.5× safu ya robo. Data ya chanzo imetolewa katika Faili ya Data ya Chanzo.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44432-3/41467_2023_44432_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par6">
     Kisha, tulitathmini muundo na kazi ya misuli ya mifupa ili kuelezea uwezo mdogo wa mazoezi kwa wagonjwa. Msongamano wa kapilari na uwiano wa kapilari-kwa-nyuzi haukutofautiana kati ya vikundi (Fig.
     <xref ref-type="fig" rid="Fig2">
      2A, B
     </xref>
     ). Hata hivyo, wagonjwa walionyesha mwelekeo wa uwiano wa chini wa kapilari-kwa-nyuzi (
     <italic>
      p
     </italic>
     = 0.08, digrii za uhuru 46), na uwiano wa kapilari-kwa-nyuzi ulilingana na V̇O
     <sub>
      2max
     </sub>
     katika vikundi vyote viwili na mteremko na makutano sawa (Fig.
     <xref ref-type="fig" rid="Fig2">
      2C
     </xref>
     ). Ikilinganishwa na udhibiti wenye afya, tuliona uwiano wa juu zaidi wa nyuzi za glycolytic zinazochoka haraka katika misuli ya vastus lateralis kwa wagonjwa wa long COVID (Fig.
     <xref ref-type="fig" rid="Fig2">
      2D
     </xref>
     , Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      4A–G
     </xref>
     ), pamoja na eneo la chini la msalaba wa nyuzi za aina I zinazostahimili uchovu kwa wanawake pekee (Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      4D–F
     </xref>
     ). Eneo la msalaba wa nyuzi lilihusishwa vyema na pato la nguvu ya juu zaidi katika vikundi vyote viwili (Fig.
     <xref ref-type="fig" rid="Fig2">
      2E
     </xref>
     ), ingawa na makutano ya chini zaidi kwa wagonjwa. Kwa ukubwa fulani wa misuli ya mifupa, wagonjwa hawakufikia pato la nguvu ya kilele sawa, ikimaanisha kuwa utendaji wa mazoezi kwa wagonjwa ulielezewa angalau kwa sehemu na mabadiliko ya ndani katika nguvu ya misuli ya mifupa na sifa za uchovu. Shughuli ya succinate dehydrogenase (SDH) (alama ya maudhui ya mitochondria) ilihusishwa na V̇O
     <sub>
      2max
     </sub>
     kwa udhibiti wenye afya, lakini si kwa wagonjwa (Fig.
     <xref ref-type="fig" rid="Fig2">
      2F
     </xref>
     ). Wakati wagonjwa walikuwa na uwezo wa chini wa phosphorylation ya oksidi (Fig.
     <xref ref-type="fig" rid="Fig3">
      3A
     </xref>
     , ED 5A–H), hakuna tofauti zilizoonekana katika shughuli ya SDH (Fig.
     <xref ref-type="fig" rid="Fig3">
      3B, C
     </xref>
     ; Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      5I, J
     </xref>
     ), ikimaanisha upumuaji wa mitochondria wa chini kwa ubora badala ya shughuli ya chini ya enzyme ya mitochondria. Kwa pamoja, data zetu zinaonyesha kuwa uwezo mdogo wa mazoezi kwa wagonjwa wa long COVID unahusishwa na uwiano mkubwa wa nyuzi za glycolytic zinazochoka haraka na kazi ya chini ya mitochondria, na uwezekano wa kizuizi cha ziada cha kapilarization ya chini na mfumo wa upumuaji.
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="en">
       <title>
        Mabadiliko ya misuli ya mifupa yanahusishwa na uwezo wa mazoezi kwa wagonjwa wenye long COVID.
       </title>
       <p>
        <bold>
         A
        </bold>
        na
        <bold>
         B
        </bold>
        mifano ya capillaries za misuli ya mifupa; hakuna tofauti za kikundi katika wingi wa capillary (
        <italic>
         p
        </italic>
        = 0.11) au uwiano wa capillary:nyuzi (
        <italic>
         p
        </italic>
        = 0.08) zilizoonekana (
        <italic>
         n
        </italic>
        = 26 long COVID,
        <italic>
         n
        </italic>
        = 21 udhibiti wenye afya).
        <bold>
         C
        </bold>
        Uhusiano muhimu ulipatikana kati ya uwiano wa capillary-nyuzi na V̇O
        <sub>
         2max
        </sub>
        kwa makundi yote mawili (
        <italic>
         n
        </italic>
        = 23 long COVID,
        <italic>
         p
        </italic>
        -value: 0.048,
        <italic>
         n
        </italic>
        = 21 udhibiti wenye afya,
        <italic>
         p
        </italic>
        -value: 0.007).
        <bold>
         D
        </bold>
        Wagonjwa wenye long COVID (
        <italic>
         n
        </italic>
        = 25) walikuwa na asilimia ya juu (
        <italic>
         p
        </italic>
        -value: 0.036) ya aina ya glycolytic IIx ikilinganishwa na udhibiti wenye afya (
        <italic>
         n
        </italic>
        = 21).
        <bold>
         E
        </bold>
        Kwa eneo fulani la msalaba wa nyuzi (FCSA), wagonjwa wenye long COVID (
        <italic>
         n
        </italic>
        = 25) walikuwa na pato la nguvu ya kilele lililopungua sana (
        <italic>
         p
        </italic>
        -value: 0.045) ikilinganishwa na watu wenye afya (
        <italic>
         n
        </italic>
        = 21).
        <bold>
         F
        </bold>
        Shughuli ya succinate dehydrogenase (SDH) katika sehemu (angalia pia Fig.
        <xref ref-type="fig" rid="Fig3">
         3
        </xref>
        ) ilihusishwa na matumizi ya juu ya oksijeni (V̇O
        <sub>
         2max
        </sub>
        ) kwa udhibiti wenye afya (
        <italic>
         n
        </italic>
        = 21,
        <italic>
         p
        </italic>
        -value: 0.0014), lakini si kwa wagonjwa wenye long COVID (
        <italic>
         n
        </italic>
        = 23,
        <italic>
         p
        </italic>
        -value: 0.66), na coefficients za uhusiano tofauti muhimu. Data za parametric endelevu zilichambuliwa kwa kutumia mtihani wa
        <italic>
         t
        </italic>
        wa pande mbili (
        <bold>
         B, D
        </bold>
        ). Mahusiano yalihesabiwa kwa kutumia Pearson wa pande mbili (
        <bold>
         C
        </bold>
        ,
        <bold>
         E
        </bold>
        ,
        <bold>
         F
        </bold>
        ). Tofauti katika intercept ilihesabiwa kwa kutumia regression ya mstari kwa kutumia ANOVA ya pande mbili (
        <bold>
         E
        </bold>
        ). Coefficients za uhusiano zililinganishwa kwa kutumia kifurushi cha R
        <italic>
         cocor
        </italic>
        . *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.001. Bar: 100 μm. Mchoro wa sanduku unaonyesha wastani (mstari wa katikati), robo ya kwanza na ya tatu (mipaka ya chini na ya juu ya sanduku), na whiskers zinaonyesha 1.5× safu ya robo. Data ya chanzo imetolewa katika Faili ya Data ya Chanzo.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44432-3/41467_2023_44432_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        Matatizo ya kimetaboliki na mitochondrial kwa wagonjwa wa long COVID yanazidi kuwa mabaya na uchovu baada ya mazoezi.
       </title>
       <p>
        <bold>
         A
        </bold>
        Uwezo wa oxidative phosphorylation (OXPHOS) ulikuwa chini sana kwa wagonjwa wa long COVID (
        <italic>
         n
        </italic>
        = 25) ikilinganishwa na udhibiti wa afya (
        <italic>
         n
        </italic>
        = 21), na ulibaki chini siku moja baada ya kuanzishwa kwa uchovu baada ya mazoezi (PEM) kwa wagonjwa (Kikundi:
        <italic>
         p
        </italic>
        = 0.003, Muda:
        <italic>
         p
        </italic>
        &lt; 0.001).
        <bold>
         B
        </bold>
        Shughuli ya succinate dehydrogenase (SDH), kiashiria cha wingi wa mitochondrial, haikuwa tofauti kati ya vikundi (
        <italic>
         p
        </italic>
        = 0.06) na ilipungua tu (
        <italic>
         p
        </italic>
        = 0.0083) baada ya kuanzishwa kwa uchovu baada ya mazoezi kwa wagonjwa wa long COVID (
        <italic>
         n
        </italic>
        = 25) ikilinganishwa na udhibiti wa afya (
        <italic>
         n
        </italic>
        = 21). Mfano wa kawaida wa shughuli ya SDH umeonyeshwa kwenye paneli
        <bold>
         C
        </bold>
        . Njia za metabolome za misuli ya mifupa (
        <bold>
         D
        </bold>
        ) na venous (
        <bold>
         E
        </bold>
        ) zinaonyesha viwango vya juu kidogo vya metabolites zinazohusiana na glycolysis, na wingi wa chini wa metabolites zinazohusiana na usanisi wa purine na mzunguko wa asidi ya tricarboxylic (TCA), ikionyesha utegemezi mdogo wa kimetaboliki ya oxidative kwa wagonjwa wa long COVID (
        <italic>
         n
        </italic>
        = 25, nyakati zote mbili) ikilinganishwa na afya (
        <italic>
         n
        </italic>
        = 19, nyakati zote mbili). Majina yaliyofifia hayakupimwa na yanaonyeshwa kwa uwazi. Ukubwa wa athari kubwa katika long COVID umeonyeshwa kwa rangi nyekundu, ukubwa wa athari ndogo kwa rangi ya bluu. Takwimu za parametric za muda mrefu (paneli
        <bold>
         A
        </bold>
        ,
        <bold>
         B
        </bold>
        ,
        <bold>
         D
        </bold>
        ,
        <bold>
         E
        </bold>
        ) zilichambuliwa kwa kutumia mfano wa mchanganyiko wa mstari wa jumla na ANOVA ya pande mbili. Vipimo vya baada ya tukio vilivyolinganishwa kila kikundi vilifanywa wakati neno la mwingiliano lilikuwa muhimu na lilifanywa kwa kutumia
        <italic>
         emmeans
        </italic>
        na marekebisho ya BH (paneli
        <bold>
         A
        </bold>
        na
        <bold>
         B
        </bold>
        ). Ukubwa wa athari (
        <bold>
         D
        </bold>
        na
        <bold>
         E
        </bold>
        ) ulipimwa kwa Hedges‘
        <italic>
         g
        </italic>
        *
        <italic>
         p
        </italic>
        &lt; 0.05; **
        <italic>
         p
        </italic>
        &lt; 0.001;
        <sup>
         †
        </sup>
        <italic>
         p
        </italic>
        &lt; 0.05 inaonyesha athari ya mwingiliano muhimu. Bar: 50 μm. PEM uchovu baada ya mazoezi. Mchoro wa sanduku unaonyesha wastani (mstari wa katikati), robo ya kwanza na ya tatu (mipaka ya chini na ya juu ya sanduku), na whiskers zinaonyesha 1.5× safu ya robo. Data ya chanzo inatolewa katika Faili ya Data ya Chanzo.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44432-3/41467_2023_44432_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Matatizo ya kimetaboliki na uchovu baada ya mazoezi
    </title>
    <p id="Par7">
     Ili kuelewa mambo ya pembeni yanayochangia maendeleo ya uchovu baada ya mazoezi, tulipata biopsi za misuli ya vastus lateralis kabla na siku moja baada ya kusababisha uchovu baada ya mazoezi. Wagonjwa wote wa long COVID walipata uchovu baada ya mazoezi kufuatia mazoezi ya juu, licha ya utofauti mkubwa katika uwezo wa mazoezi. Dalili zilijumuisha maumivu ya misuli, ukali zaidi wa uchovu, na dalili za kiakili hadi siku 7 baada ya mazoezi ya juu (Table
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     , Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      2A, B
     </xref>
     ). Ili kutathmini kwa utaratibu ikiwa dysfunction ya kimetaboliki na mitochondria inahusishwa na fiziolojia ya uchovu baada ya mazoezi, tulipima upumuaji wa mitochondria na saini za metabolomic katika misuli ya mifupa kabla na siku moja baada ya kusababisha uchovu baada ya mazoezi. Upumuaji wa mitochondria ulitathminiwa katika hali za hyperoxic ili kuepuka kizuizi cha usambazaji wa oksijeni ambacho kinaweza kuchangia kutovumilia mazoezi katika vivo. Uwezo wa phosphorylation ya oksidi ulipungua siku moja baada ya mazoezi ya juu kwa udhibiti na wagonjwa (Fig.
     <xref ref-type="fig" rid="Fig3">
      3A
     </xref>
     ). Shughuli ya SDH haikupungua kwa udhibiti wenye afya siku moja baada ya mazoezi, lakini ilipungua kwa wagonjwa wa long COVID, ikimaanisha kuwa mchanganyiko wa upumuaji wa mitochondria uliopunguzwa na maudhui ya mitochondria yaliyopungua ni sehemu ya fiziolojia ya uchovu baada ya mazoezi
     <sup>
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
     </sup>
     .
     <table-wrap id="Tab2">
      <label>
       Jedwali 2
      </label>
      <caption xml:lang="sw">
       <p>
        Dalili zilizoripotiwa na wagonjwa kabla na wakati wa uchovu baada ya mazoezi
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th>
          <p>
           Dalili
          </p>
         </th>
         <th>
          <p>
           Kiwango cha awali
          </p>
         </th>
         <th>
          <p>
           Siku 1 baada ya kuanzishwa kwa uchovu baada ya mazoezi
          </p>
         </th>
         <th>
          <p>
           Wiki 1 baada ya kuanzishwa kwa uchovu baada ya mazoezi
          </p>
         </th>
         <th>
          <p>
           <italic>
            p
           </italic>
           -thamani
          </p>
         </th>
        </tr>
        <tr>
         <th/>
         <th>
          <p>
           <italic>
            n
           </italic>
           = 25
          </p>
         </th>
         <th>
          <p>
           <italic>
            n
           </italic>
           = 25
          </p>
         </th>
         <th>
          <p>
           <italic>
            n
           </italic>
           = 25
          </p>
         </th>
         <th/>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td>
          <p>
           Uchovu
          </p>
         </td>
         <td>
          <p>
           25 (100.0)
          </p>
         </td>
         <td>
          <p>
           25 (100.0)
          </p>
         </td>
         <td>
          <p>
           24 (96.0)
          </p>
         </td>
         <td>
          <p>
           0.36
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Ukali wa uchovu ulioripotiwa binafsi (1–10), wastani [IQR]
          </p>
         </td>
         <td>
          <p>
           6.00 [4.00, 7.00]
          </p>
         </td>
         <td>
          <p>
           7.00 [7.00, 8.00]
          </p>
         </td>
         <td>
          <p>
           7.00 [6.00, 7.25]
          </p>
         </td>
         <td>
          <p>
           0.001
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Matatizo ya kiakili
          </p>
         </td>
         <td>
          <p>
           20 (80.0)
          </p>
         </td>
         <td>
          <p>
           21 (84.0)
          </p>
         </td>
         <td>
          <p>
           23 (92.0)
          </p>
         </td>
         <td>
          <p>
           0.47
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Ukali wa matatizo ya kiakili ulioripotiwa binafsi (1–10), wastani [IQR]
          </p>
         </td>
         <td>
          <p>
           4.00 [3.00, 6.25]
          </p>
         </td>
         <td>
          <p>
           6.00 [5.00, 8.00]
          </p>
         </td>
         <td>
          <p>
           6.00 [4.00, 7.00]
          </p>
         </td>
         <td>
          <p>
           0.06
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Mwili au maumivu ya viungo
          </p>
         </td>
         <td>
          <p>
           16 (64.0)
          </p>
         </td>
         <td>
          <p>
           20 (80.0)
          </p>
         </td>
         <td>
          <p>
           15 (60.0)
          </p>
         </td>
         <td>
          <p>
           0.276
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Maumivu ya kifua
          </p>
         </td>
         <td>
          <p>
           8 (32.0)
          </p>
         </td>
         <td>
          <p>
           11 (44.0)
          </p>
         </td>
         <td>
          <p>
           8 (32.0)
          </p>
         </td>
         <td>
          <p>
           0.59
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Kukosa pumzi
          </p>
         </td>
         <td>
          <p>
           6 (24.0)
          </p>
         </td>
         <td>
          <p>
           4 (16.0)
          </p>
         </td>
         <td>
          <p>
           7 (28.0)
          </p>
         </td>
         <td>
          <p>
           0.59
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Kupoteza harufu
          </p>
         </td>
         <td>
          <p>
           3 (12.0)
          </p>
         </td>
         <td>
          <p>
           3 (12.0)
          </p>
         </td>
         <td>
          <p>
           3 (12.0)
          </p>
         </td>
         <td>
          <p>
           &gt;0.99
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Maumivu ya koo
          </p>
         </td>
         <td>
          <p>
           2 (8.0)
          </p>
         </td>
         <td>
          <p>
           5 (20.0)
          </p>
         </td>
         <td>
          <p>
           3 (12.0)
          </p>
         </td>
         <td>
          <p>
           0.45
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Dalili kama za mafua
          </p>
         </td>
         <td>
          <p>
           1 (4.0)
          </p>
         </td>
         <td>
          <p>
           0 (0.0)
          </p>
         </td>
         <td>
          <p>
           2 (8.0)
          </p>
         </td>
         <td>
          <p>
           0.35
          </p>
         </td>
        </tr>
        <tr>
         <td>
          <p>
           Kikohozi
          </p>
         </td>
         <td>
          <p>
           0 (0.0)
          </p>
         </td>
         <td>
          <p>
           1 (4.0)
          </p>
         </td>
         <td>
          <p>
           1 (4.0)
          </p>
         </td>
         <td>
          <p>
           0.60
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        Takwimu za parametric endelevu zilichambuliwa kwa kutumia mtihani wa
        <italic>
         t
        </italic>
        wa pande mbili na zinaonyeshwa kama wastani na SD. Takwimu zisizo za parametric endelevu zilichambuliwa kwa kutumia mtihani wa Wilcoxon wa pande mbili na zinaonyeshwa kama wastani na safu ya kati. Thamani za
        <italic>
         p
        </italic>
        hazikurekebishwa kwa majaribio mengi. Data ya chanzo imetolewa katika Faili ya Data ya Chanzo.
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
    <p id="Par8">
     Ili kuelewa vyema kimetaboliki ya misuli ya mifupa wakati wa hali ya uchovu baada ya mazoezi, tuliorodhesha viambato 116 katika misuli ya mifupa na viambato 83 katika damu ya mshipa (Fig.
     <xref ref-type="fig" rid="Fig3">
      3D, E
     </xref>
     , Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A, B
     </xref>
     ). Biopsi za misuli ya mifupa zilipatikana wakati wa kupumzika, na ingawa viambato vya glycolytic katika misuli ya mifupa vilionyesha tofauti chache kati ya makundi, viambato muhimu vya mzunguko wa asidi ya tricarboxylic (TCA) (ikiwa ni pamoja na glutamate, FAD, alpha-ketoglutarate na asidi ya citric) vilikuwa chini katika misuli ya mifupa ya wagonjwa wa long COVID (Fig.
     <xref ref-type="fig" rid="Fig3">
      3D
     </xref>
     ). Uwiano wa asidi ya citric kwa lactate katika misuli ya mifupa ulikuwa chini kwa wagonjwa wa long COVID, ikionyesha mabadiliko kutoka kwa kimetaboliki ya oksidishaji kwa wagonjwa (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6C, D
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
     </sup>
     . Viwango vya creatine katika misuli ya mifupa vilikuwa chini kwa wagonjwa wa long COVID (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A
     </xref>
     ), labda ikichangia uwezo wa chini wa fosforilishaji wa oksidishaji kwa wagonjwa. Pia tuliona kiwango cha chini cha S-adenosylmethionine (SAM) kwa wagonjwa, labda ikihusishwa na kupungua kwa methylation na shughuli za mzunguko wa SAM kwa wagonjwa wa long COVID. Dihydroxyacetone phosphate, kiungo muhimu katika usanisi wa lipidi na glycolysis kilipungua katika misuli ya mifupa ya wagonjwa kufuatia hali ya uchovu baada ya mazoezi (Fig.
     <xref ref-type="fig" rid="Fig3">
      3D
     </xref>
     ). Asidi ya hydroxyphenyl acetic iliyo chini kwa wagonjwa kawaida inahusishwa na uzalishaji wa juu wa oksijeni tendaji katika mitochondria (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A, B
     </xref>
     )
     <sup>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     . Viambato vinavyohusiana na usanisi wa pyrimidine na purine (kama ATP), ambacho ni mchakato unaohitaji kimetaboliki, vilikuwa chini kati ya udhibiti wa afya na wagonjwa wa long COVID baada ya kuanzishwa kwa hali ya uchovu baada ya mazoezi (Fig.
     <xref ref-type="fig" rid="Fig3">
      3D
     </xref>
     , Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A
     </xref>
     ). Asidi nyingi za amino hazikuwa tofauti kati ya makundi wakati wa kupumzika, lakini zilikuwa na mwelekeo wa kuwa chini kwa wagonjwa baada ya kuanzishwa kwa hali ya uchovu baada ya mazoezi (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A
     </xref>
     ). Viambato vya glycolytic katika damu ya mshipa vilikuwa juu zaidi, lakini pyruvate na viambato vingine vya mzunguko wa TCA vilikuwa chini kwa wagonjwa ikilinganishwa na udhibiti (Fig.
     <xref ref-type="fig" rid="Fig3">
      3E
     </xref>
     ). Kuanzishwa kwa hali ya uchovu baada ya mazoezi kulisababisha kupungua kwa viambato vya glycolytic katika damu baada ya wiki moja, bila mabadiliko katika viambato vya mzunguko wa TCA kwa wagonjwa wa long COVID. Viambato mbalimbali vya damu ndani ya njia ya purine vilikuwa chini kwa wagonjwa ikilinganishwa na udhibiti (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6B
     </xref>
     ) lakini havikubadilika na kuanzishwa kwa hali ya uchovu baada ya mazoezi. Kutoka kwa uchambuzi huu, tunahitimisha kuwa viambato vya mzunguko wa TCA vilikuwa chini katika misuli ya mifupa na damu kwa wagonjwa wa long COVID, lakini havikubadilika wakati wa hali ya uchovu baada ya mazoezi. Viambato vya glycolytic katika damu ya mshipa vilikuwa juu mwanzoni na wakati wa hali ya uchovu baada ya mazoezi lakini vilipungua wiki moja baada ya kuanzishwa kwa hali ya uchovu baada ya mazoezi
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Ukusanyaji wa amiloidi unaosababishwa na mazoezi katika misuli ya mifupa
    </title>
    <p id="Par9">
     Imedhaniwa kuwa amana zenye amyloid katika mzunguko zinaweza kuzuia mtiririko wa damu wa ndani katika long COVID, na kusababisha jeraha la ischemia-reperfusion
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     . Tulichunguza kama amana zenye amyloid zilikuwepo katika misuli ya mifupa ya wagonjwa wa long COVID na kama dalili ya hali ya uchovu baada ya mazoezi ilibadilisha mkusanyiko. Tunaonyesha kuwa mkusanyiko wa amana zenye amyloid ulikuwa mkubwa zaidi katika misuli ya mifupa ya wagonjwa wa long COVID mwanzoni, na uliongezeka kwa njia sawa katika makundi yote mawili baada ya kuanzishwa kwa hali ya uchovu baada ya mazoezi (Fig.
     <xref ref-type="fig" rid="Fig4">
      4A, B
     </xref>
     ). Kama kundi la udhibiti wa ziada, biopsi za misuli ya mifupa zilizopatikana kabla ya mlipuko wa SARS-CoV-2 zilikuwa na kiasi sawa cha amana zenye amyloid kama kundi letu la udhibiti wa afya, ikithibitisha wingi wa msingi, usiohusiana na SARS-CoV-2 wa amana zenye amyloid kwa udhibiti wa afya
     <sup>
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
     </sup>
     . Kisha tulichunguza eneo la amana hizi zenye amyloid. Kuonyesha amana zenye amyloid pamoja na kapilari au mishipa ya limfu kulionyesha kuwa amana za amyloid katika misuli ya mifupa hazikuwa katika kapilari au mishipa ya limfu, bali karibu na kapilari na katika matirisi ya nje kati ya nyuzi za misuli (Fig.
     <xref ref-type="fig" rid="Fig4">
      4A, C, D
     </xref>
     ). Amana zenye amyloid hazikuingiliana na viini vya seli, ikionyesha kuwa amana hizi ziko nje ya seli zinazopenya (kinga). Tunahitimisha kuwa amana zenye amyloid hazipo ndani ya kapilari. Pia hatukuona dalili zozote za hypoxia ya tishu za misuli ya mifupa, kwani uwiano wa kapilari kwa nyuzi za misuli ya mifupa, wingi wa kapilari (Fig.
     <xref ref-type="fig" rid="Fig2">
      2B
     </xref>
     ), na viwango vya lactate vya ndani ya seli na vinavyozunguka (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     G,
     <xref ref-type="supplementary-material" rid="MOESM1">
      6A
     </xref>
     ) havikuwa tofauti kati ya wagonjwa wa long COVID na udhibiti. Kwa hivyo, tunahitimisha kuwa hali ya uchovu baada ya mazoezi haiwezi kuelezewa na dhana kwamba amana hizi zinazuia mtiririko wa damu, na kusababisha hypoxia ya tishu za ndani
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
     </sup>
     . Sababu ya msingi ya mkusanyiko wa ndani wa amana zenye amyloid wakati wa hali ya uchovu baada ya mazoezi bado haijulikani.
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        Amana zaidi zenye amyloid katika misuli ya mifupa, lakini haziko ndani ya capillaries au mishipa ya lymphatic.
       </title>
       <p>
        <bold>
         A
        </bold>
        Mfano wa kawaida wa amana zenye amyloid katika misuli ya mifupa. Sehemu za misuli ya mifupa kabla ya janga la SARS-CoV-2 zilizotiwa rangi na Thioflavin T zilionyesha viwango sawa vya amana zenye amyloid kama udhibiti wa afya.
        <bold>
         B
        </bold>
        Mkazo wa amana zenye amyloid katika misuli ya mifupa kwa wagonjwa wa long COVID (
        <italic>
         n
        </italic>
        = 24) ulikuwa juu zaidi (Kikundi:
        <italic>
         p
        </italic>
        &lt; 0.001) kuliko kwa udhibiti wa afya (
        <italic>
         n
        </italic>
        = 21) na uliongezeka kwa wagonjwa wa long COVID na udhibiti wa afya baada ya mazoezi (Muda:
        <italic>
         p
        </italic>
        = 0.008).
        <bold>
         C
        </bold>
        Amana zenye amyloid hazikupatikana ndani ya seli za endothelial, bali karibu na seli za endothelial, au kwenye matrix ya nje kati ya nyuzi. Tulifanya madoa ya amyloid kwa wagonjwa wote na kuonyesha mfano wa kawaida kwenye takwimu.
        <bold>
         D
        </bold>
        Amana zenye amyloid hazikupatikana ndani ya mishipa ya lymphatic. Takwimu za parametric za muda mrefu (paneli
        <bold>
         B
        </bold>
        ) zilichambuliwa kwa kutumia mfano wa mchanganyiko wa mstari wa jumla na ANOVA ya pande mbili. Bar: 100 μm. PEM uchovu baada ya mazoezi. Mchoro wa sanduku unaonyesha wastani (mstari wa katikati), robo ya kwanza na ya tatu (mipaka ya chini na ya juu ya sanduku), na whiskers zinaonyesha 1.5× safu ya robo. Data ya chanzo inatolewa katika Faili ya Data ya Chanzo.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44432-3/41467_2023_44432_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Myopathy inayosababishwa na mazoezi katika long COVID
    </title>
    <p id="Par10">
     Ili kufafanua zaidi pathofiziolojia ya kuongezeka kwa udhaifu wa misuli, uchovu, na maumivu baada ya mazoezi kwa wagonjwa wa long COVID, tuliamua kama vipengele maalum vya kisaikolojia vilikuwepo katika misuli ya mifupa kabla na baada ya kuanzishwa kwa hali ya uchovu baada ya mazoezi. Kwa kuwa ukubwa wa biopsi ulikuwa tofauti kati ya washiriki na wakati, tulipima biopsi hasi/chanya kwa vigezo vya kisaikolojia na kinga. Asilimia kubwa ya wagonjwa wa long COVID ilionyesha nyuzi ndogo za atrophic na necrosis ya sehemu (Fig.
     <xref ref-type="fig" rid="Fig5">
      5A, B
     </xref>
     ), ambayo iliongezeka kwa kiasi kikubwa baada ya mazoezi, ikionyesha majibu ya uharibifu wa tishu kwa wagonjwa wa long COVID. Kwa kuwa misuli ya mifupa ni tishu inayobadilika, dalili za urejeshaji wa misuli ya mifupa, kama vile viini vilivyowekwa katikati (Fig.
     <xref ref-type="fig" rid="Fig5">
      5C
     </xref>
     ), zilikuwa dhahiri zaidi kwa wagonjwa wa long COVID, pia kabla ya kuanzishwa kwa hali ya uchovu baada ya mazoezi. Nyuzi zinazorejea haraka, zinazoonyeshwa na viini vya katikati na sitoplazimu ya basophilic, zilionekana katika biopsi kutoka kwa makundi yote mawili (Fig.
     <xref ref-type="fig" rid="Fig5">
      5D
     </xref>
     ), na mazoezi makali yaliongeza uwiano wa nyuzi zinazorejea kwa udhibiti wa afya na wagonjwa wa long COVID bila tofauti za kundi. Tunahitimisha kuwa uharibifu mkubwa wa misuli unaosababishwa na mazoezi na urejeshaji unaofuata unahusishwa na pathofiziolojia ya hali ya uchovu baada ya mazoezi, na inaweza kuelezea maumivu ya misuli, uchovu, na udhaifu kwa wagonjwa wa long COVID wanaopata hali ya uchovu baada ya mazoezi.
     <fig id="Fig5" position="float">
      <label>
       Fig. 5
      </label>
      <caption xml:lang="en">
       <title>
        Sifa za kimaumbile katika misuli ya mifupa kwa wagonjwa wenye long COVID.
       </title>
       <p>
        <bold>
         A
        </bold>
        Nyuzi ndogo sana na zilizopinda za atrofia zilikuwa nyingi zaidi kwa wagonjwa wenye long COVID na katika sampuli za baadaye za misuli baada ya mazoezi katika makundi yote mawili (Kundi:
        <italic>
         p
        </italic>
        &lt; 0.001).
        <bold>
         B
        </bold>
        Maeneo makubwa ya nyuzi zilizokufa yalionekana kwa 36% ya wagonjwa wenye long COVID baada ya mazoezi makali (Thamani ya p ya kundi: 0.09, ikilinganishwa na udhibiti wenye afya.
        <bold>
         C
        </bold>
        Nuclei za ndani, zinazoashiria ukarabati wa nyuzi, zilikuwa nyingi zaidi kwa kiasi kikubwa (Kundi:
        <italic>
         p
        </italic>
        = 0.002) katika misuli ya mifupa ya wagonjwa wenye long COVID, lakini hazikuongezeka wakati wa hali ya uchovu baada ya mazoezi (PEM).
        <bold>
         D
        </bold>
        Nyuzi za kuzaliwa upya hazikuwa tofauti kati ya makundi, lakini zilikuwa nyingi zaidi katika sampuli za baadaye za misuli baada ya mazoezi (Muda:
        <italic>
         p
        </italic>
        &lt; 0.001).
        <bold>
         E
        </bold>
        : Wagonjwa wengi zaidi wenye long COVID walikuwa na kuingizwa kwa seli za CD3+ T (Kundi:
        <italic>
         p
        </italic>
        = 0.046).
        <bold>
         F
        </bold>
        Uwepo wa macrophages za CD68+ ulikuwa juu zaidi kwa wagonjwa wenye long COVID (Kundi:
        <italic>
         p
        </italic>
        = 0.03).
        <bold>
         G
        </bold>
        Seli za CD20+ B hazikuwepo kwa wingi katika misuli ya mifupa. Paneli zote:
        <italic>
         n
        </italic>
        = 25 long COVID,
        <italic>
         n
        </italic>
        = 21 udhibiti wenye afya. Data za muda mrefu za kategoria zilichambuliwa kwa kutumia usajili wa kimantiki na "muda" kama kigezo. Ulinganisho wa baada ya tukio (
        <bold>
         E
        </bold>
        ) ulifanywa kwa kutumia Tofauti za Kati za Kimaumbile kwa kutumia kifurushi cha R
        <italic>
         emmeans
        </italic>
        na marekebisho ya BH. Upau: 100 μm. Kifupi: PEM; hali ya uchovu baada ya mazoezi. Data ya chanzo imetolewa katika Faili ya Data ya Chanzo.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44432-3/41467_2023_44432_Fig5_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par11">
     Kisha, tulichunguza upenyaji wa seli za kinga (macrophages, T- na B-cells) katika misuli ya mifupa baada ya mazoezi makali. Wagonjwa wengi wa long COVID walikuwa na upenyaji wa macrophage za CD68 katika misuli ya mifupa ikilinganishwa na udhibiti wa afya (Fig.
     <xref ref-type="fig" rid="Fig5">
      5E
     </xref>
     ). Mazoezi yalisababisha ongezeko sawa la macrophage zinazopenya katika makundi yote mawili. Seli za T za CD3 hazikuwepo kwa udhibiti wa afya, lakini zilikuwepo kwa wagonjwa wa long COVID kabla ya kuanzishwa kwa hali ya uchovu baada ya mazoezi (Fig.
     <xref ref-type="fig" rid="Fig5">
      5F
     </xref>
     ). Mazoezi yalisababisha mkusanyiko wa seli za T za CD3 ndani ya tishu za misuli ya mifupa, lakini majibu haya yalipunguzwa kwa wagonjwa wanaopata hali ya uchovu baada ya mazoezi. Seli za B za CD20 hazikuwa tofauti kati ya makundi na zilikuwa na mwelekeo wa kuwa juu siku moja baada ya mazoezi (Fig.
     <xref ref-type="fig" rid="Fig5">
      5G
     </xref>
     )
     <sup/>
     .
    </p>
    <p id="Par12">
     Tulidhani kuwa uharibifu unaosababishwa na mazoezi na upenyaji wa seli za kinga unaweza kuwa kutokana na vipande vya DNA ya mitochondria (mtDNA) vinavyozunguka katika mzunguko wa mfumo, ambavyo hufanya kama muundo unaohusishwa na uharibifu unaosababisha majibu ya uchochezi wa mfumo
     <sup>
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     . Hata hivyo, hatukupata ushahidi wowote wa majibu ya mtDNA inayozunguka kwa kiasi kikubwa katika plasma kutoka kwa wagonjwa ikilinganishwa na udhibiti (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      7A–F
     </xref>
     ). Pia hatukuona ongezeko la bidhaa za uharibifu wa misuli, kama vile creatinine na creatine kinase, katika plasma ya makundi yote mawili (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      6
     </xref>
     B na
     <xref ref-type="supplementary-material" rid="MOESM1">
      7G, H
     </xref>
     ). Viwango vya cortisol vinavyozunguka, ambavyo ni muhimu kwa kudhibiti majibu ya mfadhaiko wa homeostatic, havikuwa tofauti kati ya makundi wakati wa kipimo, na bila marekebisho kwa wakati tangu kuamka (Mchoro wa Ziada
     <xref ref-type="supplementary-material" rid="MOESM1">
      7I
     </xref>
     ).
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Uwepo wa nucleocapsid ya SARS-CoV-2 katika misuli ya mifupa
    </title>
    <p id="Par13">
     Ili kubaini kama mabaki ya virusi yana jukumu katika majibu tofauti ya kinga kwenye misuli ya mifupa katika long COVID baada ya kuanzishwa kwa uchovu baada ya mazoezi, tulipaka rangi sehemu zote za misuli kwa protini ya nucleocapsid ya SARS-CoV-2. Tulifikiri kwamba kama uwepo wa virusi unachangia, basi protini ya nucleocapsid ya SARS-CoV-2, ambayo ni maalum kwa SARS-CoV-2 na haiathiriwi na chanjo, inapaswa kuwa angalau ipo. Ingawa hatukuona upakaji rangi chanya katika sampuli zilizopatikana kabla ya mlipuko wa SARS-CoV-2 (Fig.
     <xref ref-type="fig" rid="Fig6">
      6A, B
     </xref>
     ), tulipata protini ya nucleocapsid ya SARS-CoV-2 karibu kwa wagonjwa wote na udhibiti wenye afya (Fig.
     <xref ref-type="fig" rid="Fig6">
      6A, B
     </xref>
     ). Licha ya muda mrefu zaidi tangu maambukizi ya mwisho kwa wagonjwa wa long COVID, kiasi cha protini ya nucleocapsid ya SARS-CoV-2 hakikuwa tofauti kati ya makundi (Fig.
     <xref ref-type="fig" rid="Fig6">
      6A
     </xref>
     ), kabla na baada ya kurekebisha kwa muda tangu maambukizi ya mwisho. Washiriki wenye maambukizi &gt;6 miezi kabla ya kujiandikisha kwenye utafiti hawakuonyesha tofauti katika wingi wa protini ya nucleocapsid ya SARS-CoV-2, lakini hatuwezi kuondoa maambukizi ya ziada yasiyo na dalili. Protini ya nucleocapsid ya SARS-CoV-2 haikuwa ndani ya nyuzi za misuli, bali katika matiriksi ya nje ya seli, hata hivyo, uwepo wake haukuendana mara kwa mara na viini vya seli. Hakukuwa na uhusiano kati ya uwepo wa protini ya nucleocapsid ya SARS-CoV-2 na amana zenye amyloid (
     <italic>
      R
     </italic>
     = 0.03). Mkazo wa protini ya nucleocapsid ya SARS-CoV-2 haukubadilika baada ya maendeleo ya uchovu baada ya mazoezi. Matokeo yetu yanapendekeza kwamba uwepo wa mabaki ya protini ya nucleocapsid ya SARS-CoV-2 ni sawa kati ya wagonjwa na udhibiti wenye afya, na kwa hivyo hauelezei uwezo mdogo wa mazoezi au maendeleo ya uchovu baada ya mazoezi kwa wagonjwa wenye long COVID
     <sup>
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR37">
       37
      </xref>
     </sup>
     .
     <fig id="Fig6" position="float">
      <label>
       Fig. 6
      </label>
      <caption xml:lang="en">
       <title>
        Viwango sawa vya protini ya nucleocapsid katika misuli ya mifupa kwa wagonjwa wenye long COVID kama udhibiti.
       </title>
       <p>
        <bold>
         A
        </bold>
        Protini ya nucleocapsid ya SARS-CoV-2 ilikuwepo kwa karibu washiriki wote, lakini haikuwa nyingi zaidi kwa long COVID (
        <italic>
         n
        </italic>
        = 23) ikilinganishwa na udhibiti wenye afya (
        <italic>
         n
        </italic>
        = 19).
        <bold>
         B
        </bold>
        Mifano ya kawaida ya protini ya nucleocapsid ya SARS-CoV-2, kama alama ya kuendelea kwa virusi, katika misuli ya mifupa. Sampuli za misuli ya mifupa kutoka kabla ya janga la SARS-CoV-2 hazikuonyesha ishara yoyote wakati zilipopakwa rangi na IgG ya polyclonal dhidi ya protini ya nucleocapsid ya SARS-CoV-2, ikionyesha kuwa protini ya nucleocapsid ya SARS-CoV-2 haikuwepo kwa watu ambao hawakuambukizwa ambayo ilithibitisha kuwa hakukuwa na uhusiano usio maalum. Data za muda mrefu za parametric (paneli
        <bold>
         A
        </bold>
        ) zilichambuliwa kwa kutumia mfano wa mchanganyiko wa mstari wa jumla na ANOVA ya pande mbili. Upau: 100 μm. PEM hali ya uchovu baada ya mazoezi. Mchoro wa sanduku unaonyesha wastani (mstari wa katikati), robo ya kwanza na ya tatu (mipaka ya chini na ya juu ya sanduku), na mikia inaonyesha mara 1.5 ya safu ya robo. Data ya chanzo imetolewa katika Faili ya Data ya Chanzo.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44432-3/41467_2023_44432_Fig6_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
  </sec>
  <sec id="Sec8" sec-type="discussion">
   <title>
    Majadiliano
   </title>
   <p id="Par14">
    Tulilenga kufafanua pathofiziolojia ya uwezo mdogo wa mazoezi na uchovu baada ya mazoezi kwa wagonjwa wenye long COVID na kufichua kasoro za kipekee za pathofiziolojia katika misuli ya mifupa na damu kwa wagonjwa wa long COVID kwa kutumia muundo wa utafiti wa muda mrefu, wa kesi na udhibiti. Wagonjwa wenye long COVID walionyesha uwezo mdogo wa mazoezi, ambao ulihusiana na mabadiliko ya kimetaboliki ya misuli ya mifupa na mabadiliko kuelekea nyuzi zinazochoka haraka zaidi. Pathofiziolojia ya uchovu baada ya mazoezi inajumuisha kupungua kwa ghafla kwa shughuli za kimeng'enya ya mitochondrial ya misuli ya mifupa, kuongezeka kwa mkusanyiko wa amana zenye amyloid katika misuli ya mifupa, ishara za uharibifu mkubwa wa tishu za misuli, pamoja na majibu ya T-cell yaliyopunguzwa kutokana na mazoezi katika misuli ya mifupa. Kwa pamoja, matokeo haya husaidia kufafanua fiziolojia ya msingi ya uchovu na uwezo mdogo wa mazoezi kutoka kwa maendeleo ya uchovu baada ya mazoezi kwa wagonjwa wenye long COVID.
   </p>
   <p id="Par15">
    Uwezo mdogo wa mazoezi ni moja ya alama kuu za long COVID, inayohusishwa na mzigo mkubwa kwa maisha ya kila siku
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
    </sup>
    . Mfumo wa upumuaji na mfumo wa moyo na mishipa haukuzuia uwezo wa mazoezi kwa wagonjwa wa long COVID, lakini matokeo yetu yanathibitisha mapendekezo ya awali ya upungufu wa pembeni katika kimetaboliki ya misuli ya mifupa kwa wagonjwa wa long COVID
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     ,
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
     ,
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    . Sambamba na dhana za awali, tunaonyesha kwamba long COVID inahusishwa na uwezo mdogo wa fosforilishaji wa oksidi wa misuli ya mifupa. Uwepo wa nyuzi za mseto za IIA/X na nyuzi za nadra za mseto za I/IIA kwa wagonjwa wa long COVID unapendekeza kwamba pathofiziolojia ya long COVID inajumuisha mabadiliko ya aina ya nyuzi kuelekea fenotipu isiyo na oksidi zaidi, inayotumia glycolytic zaidi. Mabadiliko ya kimetaboliki na kimuundo yanaungwa mkono na metabolomes za damu ya vena na misuli ya mifupa ya wagonjwa wa long COVID, ambapo metabolites za glycolytic zilikuwa juu na metabolites za mzunguko wa TCA zilikuwa chini. Tuliona kwamba mabadiliko ya aina ya nyuzi na kupungua kwa upumuaji wa mitochondrial vinahusishwa na uwezo mdogo wa mazoezi kwa wagonjwa, lakini haya hayachangii lazima kwa pathofiziolojia ya uchovu baada ya mazoezi, kwani mabadiliko ya aina ya nyuzi hutokea kwa kasi ndogo sana na yanaweza kuwa yalikuwepo kabla ya long COVID. Washiriki wetu walionyesha utofauti mkubwa katika uvumilivu wa mazoezi (V̇O
    <sub>
     2max
    </sub>
    na nguvu ya kilele), muundo wa aina ya nyuzi, na shughuli za kimeng'enya ya mitochondrial, lakini licha ya utofauti huu mkubwa, wagonjwa wote walipata uchovu baada ya mazoezi siku moja baada ya mtihani wa mazoezi. Kwa hivyo, tunahitimisha kwamba pathofiziolojia ya uchovu na uwezo mdogo wa mazoezi ni tofauti na maendeleo ya haraka ya uchovu baada ya mazoezi kwa wagonjwa wa long COVID. Maendeleo ya uchovu baada ya mazoezi yanaweza, hata hivyo, kusababisha kupungua zaidi kwa uwezo wa mazoezi kwa wagonjwa, kwani kupungua kwa ghafla kwa shughuli za SDH ya mitochondrial, kutokea kwa necrosis ya tishu, na labda mkusanyiko wa ndani ya misuli wa amana zenye amyloid kunaweza kuzidisha kimetaboliki ya misuli ya mifupa na uzalishaji wa nguvu kwa muda, na kusababisha mzunguko mbaya wa kushuka chini
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     ,
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
    </sup>
    .
   </p>
   <p id="Par16">
    Hypoxia ya tishu, inayosababishwa na mkusanyiko wa amana zenye amyloid katika capillaries ndogo zaidi imependekezwa kuchangia dalili za long COVID, kama vile uchovu
    <sup>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
     ,
     <xref ref-type="bibr" rid="CR40">
      40
     </xref>
    </sup>
    . Tulipata upungufu wa uchimbaji wa oksijeni wa pembeni (na deoxygenation ya chini kiasi) na mkusanyiko wa juu wa amana zenye amyloid katika misuli ya mifupa, lakini hatukupata ushahidi wa capillaries zilizozibwa ndani ya misuli ya mifupa. Matokeo yetu kwa hivyo hayaungi mkono dhana ya hypoxia ya tishu sugu kutokana na kuzibwa kwa mishipa kuchangia maendeleo ya dalili zinazohusiana na misuli ya mifupa katika long COVID au uchovu baada ya mazoezi. Tulitathmini tu uwepo wa amyloid, lakini si kazi ya endothelium, au mtiririko wa damu wa ndani. Kwa hivyo, uhusiano unaowezekana wa endotheliitis sugu au mtiririko wa damu uliopunguzwa kwa maendeleo ya uchovu baada ya mazoezi na/au uvumilivu wa mazoezi katika long COVID unabaki wazi
    <sup>
     <xref ref-type="bibr" rid="CR41">
      41
     </xref>
     ,
     <xref ref-type="bibr" rid="CR42">
      42
     </xref>
    </sup>
    . Uchunguzi zaidi katika muundo wa amana hizi zenye amyloid na jukumu linalowezekana la kingamwili zilizofungiwa (auto-) kuhusiana na uchovu baada ya mazoezi na long COVID unahitajika
    <sup>
     <xref ref-type="bibr" rid="CR43">
      43
     </xref>
    </sup>
    .
   </p>
   <p id="Par17">
    Vikundi vyote viwili vilionyesha nyuzi zaidi zinazorejea baada ya biopsy ya pili, ikionyesha athari inayowezekana ya biopsy ya kwanza. Licha ya hili, wagonjwa wa long COVID walikuwa na viini vya ndani zaidi, nyuzi za atrophic, na necrosis ya sehemu baada ya kuanzishwa kwa uchovu baada ya mazoezi ikilinganishwa na udhibiti wenye afya. Atrophy ya misuli ya mifupa na necrosis ya sehemu inaweza kutokea wakati wa maambukizi makali ya SARS-CoV-2, lakini huu ni utafiti wa kwanza kutoa ushahidi wa uharibifu mkubwa wa tishu baada ya mazoezi makali kwa wagonjwa wa long COVID. Uingizaji wa juu wa misuli ya mifupa wa macrophages wa CD68 na seli za T za CD3 unapendekeza majibu ya kinga yaliyovurugika kwa wagonjwa wenye long COVID
    <sup>
     <xref ref-type="bibr" rid="CR44">
      44
     </xref>
     ,
     <xref ref-type="bibr" rid="CR45">
      45
     </xref>
    </sup>
    .
   </p>
   <p id="Par18">
    Magonjwa ya virusi yanaweza kubadilisha kazi ya mitochondria, na tafiti kadhaa zimeonyesha kuwa uwepo wa protini ya mabaki ya SARS-CoV-2 unahusishwa na long COVID
    <sup>
     <xref ref-type="bibr" rid="CR43">
      43
     </xref>
     ,
     <xref ref-type="bibr" rid="CR46">
      46
     </xref>
     ,
     <xref ref-type="bibr" rid="CR47">
      47
     </xref>
    </sup>
    . Wakati wa maambukizi makali ya SARS-CoV-2, kiwango cha protini ya nucleocapsid ya SARS-CoV-2 huongezeka kwa kasi, na ingawa wagonjwa wetu walipata myopathy inayosababishwa na mazoezi, hakukuwa na dalili za uwepo wa juu wa protini ya nucleocapsid ya SARS-CoV-2 kwa wagonjwa wenye long COVID kabla au baada ya kuanzishwa kwa hali ya uchovu baada ya mazoezi. Zaidi ya hayo, hatukuona kuongezeka kwa seli za B katika misuli ya mifupa ya wagonjwa kabla na wakati wa hali ya uchovu baada ya mazoezi. Uwepo wa protini ya nucleocapsid ya SARS-CoV-2 katika misuli ya mifupa hauwashangazi, kwani protini ya nucleocapsid inaweza kuwepo hadi mwaka mmoja baada ya maambukizi katika damu
    <sup>
     <xref ref-type="bibr" rid="CR48">
      48
     </xref>
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
     ,
     <xref ref-type="bibr" rid="CR50">
      50
     </xref>
    </sup>
    . Hata hivyo, haijulikani ikiwa virusi kamili vipo, au ni mabaki ya protini tu. Kwa sababu protini ya spike iko kwenye nje ya virusi, protini hii inaweza kuwa na athari tofauti za uchochezi/ugandaji ikilinganishwa na protini ya nucleocapsid. Ukosefu wa tofauti wazi katika kiasi cha protini ya nucleocapsid na uwepo sawa wa seli za B na T baada ya mazoezi unapendekeza kuwa mambo mengine zaidi ya kuendelea kwa virusi yanahusishwa na pathofiziolojia ya hali ya uchovu baada ya mazoezi kwa wagonjwa wenye long COVID.
   </p>
   <p id="Par19">
    Utafiti huu ni wa uchunguzi kiasili, na kwa hivyo hatuwezi kuanzisha uhusiano wa kisababishi. Tulijumuisha tu watu wenye long COVID kali, lakini kasoro zilizogunduliwa hazionyeshi ukosefu wa shughuli za mwili. Data ya accelerometer ilionyesha kuwa wagonjwa wa long COVID hawakuwa kitandani, na walikuwa na wastani wa hatua ~4000 kwa siku (Supplemental Fig.
    <xref ref-type="supplementary-material" rid="MOESM1">
     2C
    </xref>
    ). Ingawa kundi letu linaweza kuwa lilionyesha tabia ya kukaa tu, ukosefu wa shughuli za mwili wenyewe hauleti hali ya uchovu baada ya mazoezi na unahusishwa na atrophy ya misuli na shughuli ya chini ya SDH ya mitochondria, ambayo hatukuona katika uchambuzi wetu wa msalaba. Kwa kuwa ukubwa wa sampuli ya utafiti huu ni mdogo kiasi, matokeo yetu yanahitaji kurudiwa katika makundi mengine. Kwa kuunga mkono kazi yetu, mabadiliko ya pembeni katika kimetaboliki ya mitochondria na myopathy yameonekana hivi karibuni kwa wagonjwa wenye long COVID, lakini jinsi hali ya uchovu baada ya mazoezi inavyobadilisha mabadiliko ya misuli ya mifupa inahitaji uthibitisho zaidi. Hali ya uchovu baada ya mazoezi ni dalili maalum kwa baadhi ya makundi ya wagonjwa, ikiwa ni pamoja na long COVID na myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Ingawa haiwezekani kwamba pathofiziolojia ya hali ya uchovu baada ya mazoezi ni tofauti kabisa, kazi ya baadaye inapaswa kuangazia ikiwa pathofiziolojia ya msingi ni sawa katika makundi yote ya wagonjwa, ikiwa ni pamoja na watoto na vijana
    <sup>
     <xref ref-type="bibr" rid="CR51">
      51
     </xref>
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     ,
     <xref ref-type="bibr" rid="CR52">
      52
     </xref>
     <xref ref-type="bibr" rid="CR53">
      53
     </xref>
    </sup>
    .
   </p>
   <p id="Par20">
    Kwa kumalizia, utafiti huu unaonyesha kuwa usumbufu wa kimetaboliki ya ndani na ya mfumo mzima, myopathy kali inayosababishwa na mazoezi, kuingizwa kwa amana zenye amyloid, na seli za kinga katika misuli ya mifupa ya long COVID ni sifa kuu za hali ya uchovu baada ya mazoezi. Ingawa haya yanaelezea dalili za hali ya uchovu baada ya mazoezi katika long COVID, njia za molekuli zinazohusiana na mabadiliko haya kwa wagonjwa wanaosumbuliwa na hali ya uchovu baada ya mazoezi bado hazijabainishwa.
   </p>
  </sec>
  <sec id="Sec9" sec-type="methods">
   <title>
    Mbinu
   </title>
   <sec id="Sec10">
    <title>
     Idadi ya watu waliohusika katika utafiti
    </title>
    <p id="Par21">
     Tulifanya utafiti wa kesi-kudhibiti wa mbele katika kliniki ya baada ya COVID-19 ya Vituo vya Matibabu vya Chuo Kikuu cha Amsterdam (UMC) na Kitivo cha Sayansi ya Tabia na Harakati (Vrije Universiteit Amsterdam). Itifaki ya utafiti iliidhinishwa na kamati ya maadili ya matibabu ya Amsterdam UMC (NL78394.018.21) na kusajiliwa katika
     <ext-link ext-link-type="uri" href="http://www.clinicaltrials.gov">
      www.clinicaltrials.gov
     </ext-link>
     (NCT05225688). Washiriki wote walitia saini idhini iliyoandikwa kabla ya kushiriki. Utafiti ulifanywa kwa mujibu wa Azimio la Helsinki.
    </p>
    <p id="Par22">
     Wagonjwa wa long COVID waligunduliwa na madaktari wawili wenye uzoefu kwa dalili za long COVID na kuondolewa kwa utambuzi tofauti unaowezekana. Wagonjwa wote wa long COVID waligunduliwa na hali ya uchovu baada ya mazoezi (PEM) na DSQ-PEM, walikuwa na kipindi cha chini cha miezi sita cha dalili zinazohusiana na long COVID, na walikuwa kati ya umri wa miaka 18 na 65. Hakuna dalili zilizokuwepo kabla ya utambuzi uliothibitishwa wa SARS-CoV-2. Hojaji kuhusu uchovu, alama ya ukali wa uchovu (FSS), hesabu ya uchovu wa vipengele vingi (MFI), na DSQ-PEM zilipatikana katika kipindi chote cha utafiti. Hakuna mshiriki aliyejumuishwa alilazwa hospitalini wakati wa maambukizi makali ya SARS-CoV-2 na walikuwa na afya kabla ya NAAT au maambukizi ya SARS-CoV-2 yaliyothibitishwa na serolojia. Vigezo vya kutengwa vilikuwa historia ya matibabu ya ugonjwa wa moyo/ugonjwa wa mapafu, kisukari, matibabu ya wakati huo na dawa zinazobadilisha kimetaboliki au kuganda wakati wa kipindi cha utafiti (statins, corticosteroids, SGLT2 inhibitors, GLP1 receptor agonists, vizuizi vya mkusanyiko wa sahani na dawa yoyote ya kugandisha damu), unene lakini sio BMI (kupunguza biopsy ya musculus vastus lateralis), ujauzito, maambukizi hai, dysfunction kali ya figo au ugonjwa mwingine wowote wa muda mrefu unaojulikana kuathiri utendaji wa kliniki au &gt;vitengo 6 vya pombe kwa siku au &gt;vitengo 14 vya pombe kwa wiki. Uvutaji sigara haukuwa kigezo cha kutengwa
     <sup>
      <xref ref-type="bibr" rid="CR54">
       54
      </xref>
      <xref ref-type="bibr" rid="CR55">
       55
      </xref>
      <xref ref-type="bibr" rid="CR56">
       56
      </xref>
     </sup>
     .
    </p>
    <p id="Par23">
     Hakuna kati ya udhibiti wa afya aliyekuwa na dalili zilizobaki baada ya maambukizi ya SARS-CoV-2. Mgonjwa mmoja wa long COVID aliondolewa kutokana na maambukizi mapya ya SARS-CoV-2 (&lt;siku 7). Udhibiti wa afya uliondolewa kwa sababu ya asili ya uvamizi ya itifaki (
     <italic>
      n
     </italic>
     = 2), dalili zinazohusiana na uchovu mwingi (
     <italic>
      n
     </italic>
     = 1), na utambuzi mpya wa shinikizo la damu lisilodhibitiwa (
     <italic>
      n
     </italic>
     = 1).
    </p>
   </sec>
   <sec id="Sec11">
    <title>
     Muundo wa utafiti
    </title>
    <p id="Par24">
     Washiriki wote walifuata itifaki sawa ya utafiti (Supplemental Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ), na ziara nne katika kipindi cha wiki mbili. Washiriki walifika maabara angalau masaa mawili baada ya kula na waliagizwa kuepuka kafeini siku ya ziara ya maabara. Uchovu baada ya mazoezi ulisababishwa na mtihani wa mazoezi ya kiwango cha juu siku ya 7. Biopsi za misuli ya mifupa zilichukuliwa kutoka kwa vastus lateralis siku ya 1 (kabla) na siku ya 8 (siku 1 baada ya mtihani wa mazoezi) kwa kutumia sindano ya Bergström inayosaidiwa na kuvuta (Pelomi, Albertlund, Denmark). Biopsi zote mbili zilichukuliwa kutoka kwa sehemu ile ile ya ~2 cm; biopsi ya kwanza ilichukuliwa kuelekea mwisho wa karibu wa misuli na biopsi ya pili ilichukuliwa kuelekea sehemu ya mbali ya misuli. Sampuli zilihifadhiwa kwenye −195 °C hadi uchambuzi wa baadaye, au kuhifadhiwa kama ilivyoelezwa vinginevyo. Damu ya mshipa ilichukuliwa katika kila ziara. Damu iliyotiwa anticoagulant ya Ethylenediaminetetraacetic acid (EDTA) ilipatikana katika kila ziara, na plasma ilihifadhiwa kwenye −70 °C ndani ya masaa 4. Orodha ya strobe inaweza kupatikana katika faili ya data ya ziada.
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     Jaribio la mazoezi ya kuongeza hatua kwa hatua
    </title>
    <p id="Par25">
     Ili kutathmini uvumilivu wa mazoezi na kusababisha uchovu baada ya mazoezi kwa wagonjwa wa long COVID, tulifanya mtihani wa mazoezi ya kiwango cha juu kwenye ergometer ya baiskeli na kipimo cha ECG, kubadilishana gesi ya mapafu/ventilation na upungufu wa oksijeni kwenye misuli. Vipimo vyote vya mazoezi vilifanywa kwenye ergometer ya baiskeli inayodhibitiwa kielektroniki (Lode Excalibur Sport, Lode, Groningen, Uholanzi). Mtihani ulitanguliwa na mapumziko ya dakika 2 kwenye ergometer na kuendesha baiskeli kwa kiwango cha chini kwa dakika 4 (kati ya 0 na 20 W kulingana na urefu, uzito wa mwili na kiwango cha usawa kinachotarajiwa). Hii ilifuatiwa na ongezeko la kazi kwa mstari hadi kushindwa kwa kazi. Viwango vya kazi vya msingi vya mtu binafsi na miteremko ya kiwango vilichaguliwa kulingana na sifa za anthropometric za kila mshiriki na viwango vya shughuli za mwili na vilibuniwa kusababisha kushindwa kwa kazi ndani ya dakika 8-12. Washiriki waliagizwa kudumisha mwendo kati ya mizunguko 70 na 90 kwa dakika, na kushindwa kwa kazi kulifafanuliwa kama hatua ambayo mwendo ulipungua &lt;mizunguko 60 kwa dakika licha ya kuhamasishwa kwa maneno. Viwango vya lactate ya kapilari vilibainishwa wakati wa kupumzika kabla ya kuanza kwa mtihani, wakati wa kuendesha baiskeli kwa msingi, na mara baada ya kushindwa kwa kazi (Lactate Pro 2 LT-1730, ARKRAY Ltd., Uingereza). Kubadilishana gesi ya mapafu na ventilation vilipimwa kwa msingi wa pumzi kwa pumzi (Cosmed Quark CPET; Cosmed, Roma, Italia).
    </p>
    <sec id="Sec13">
     <title>
      Spectroskopia ya karibu-infrared (NIRS)
     </title>
     <p id="Par26">
      Washiriki walivaa kifaa cha NIRS kinachobebeka chenye urefu wa mawimbi unaoendelea (Portamon, Artinis Medical Systems, Arnhem, Uholanzi) juu ya uso wa misuli ya vastus lateralis, katikati ya kichwa cha femur na kondili ya pembeni. Hii ilikuwa karibu na eneo la biopsi ya misuli. Vipimo vya jumla (Δtotal[heme]), heme isiyo na oksijeni (Δdeoxy[heme]) na heme yenye oksijeni (Δoxy[heme]) [hemoglobini + myoglobini], pamoja na saturation ya misuli (SO
      <sub>
       2
      </sub>
      , yaani, oxy[heme]/total[heme]·100) vilinormalishwa kwa thamani ya juu na ya chini iliyopatikana wakati wa kuzuiliwa kwa mtiririko wa damu karibu na kifaa cha NIRS kwa kutumia kifuniko kinachoweza kupulizwa. Kwa ufupi, kifuniko kilipulizwa kati ya 300–500 mmHg, na kilibaki kimepulizwa hadi plateau katika ishara za Δtotal[heme], Δdeoxy[heme], na Δoxy[heme] zilipofikiwa, na kisha kuachiliwa. Thamani ya juu na ya chini ilitoa kiwango cha kisaikolojia kwa kila mtu, na thamani zote zilinormalishwa kwa kiwango hiki cha kisaikolojia. Kwa kuwa umbali mkubwa zaidi wa kutenganisha chanzo na detector wa kifaa cha NIRS ulikuwa 40 mm, washiriki wenye unene wa tishu za mafuta ≥20 mm (au unene wa ngozi ≥40 mm) waliondolewa kutoka kwa uchambuzi huu. Hii ilisababisha kujumuishwa kwa udhibiti 18 na wagonjwa 16 katika uchambuzi wa mwisho. Data ya Δdeoxy[heme] ya mtu binafsi ilihesabiwa wastani kama kazi ya pato la nguvu kabisa na la jamaa. Data zote za NIRS zilichambuliwa kuhusiana na viwango vya kazi kabisa na vya jamaa. Viwango vya kazi kabisa vilichambuliwa kwa ongezeko la 25 W kutoka 50 W hadi 175 W, baada ya hapo washiriki wengi hawakuweza kuendelea na mtihani. Data ya NIRS ilihesabiwa wastani kwa 5 W chini na juu ya kila ongezeko ili kupunguza kelele katika seti ya data. Vivyo hivyo, kwa viwango vya kazi vya jamaa, data ilichambuliwa kwa 0%, 20%, 40%, 60%, 80%, na 100% ya kiwango cha juu cha kazi. Data ilihesabiwa wastani kwa 5% juu na chini ya kila ongezeko. Data zote zilichambuliwa baadaye kwa kutumia mfano wa mchanganyiko wa mstari.
     </p>
    </sec>
   </sec>
   <sec id="Sec14">
    <title>
     Kiwango cha shughuli za kimwili za maisha ya kila siku
    </title>
    <p id="Par27">
     Shughuli ya jumla ya kila siku ilipimwa na accelerometer (Actigraph wGT3X-BT, muda wa sampuli 60 Hz) iliyovaliwa kwenye kiuno cha kulia (mstari wa mbele wa axillary) wakati wa kipindi chote cha utafiti, kama ilivyoelezwa hapo awali
     <sup>
      <xref ref-type="bibr" rid="CR57">
       57
      </xref>
     </sup>
     . Washiriki waliagizwa kuvaa accelerometer kuanzia asubuhi mapema hadi wakati wa kulala. Kiwango cha shughuli za mwili za kila siku kilibainishwa na idadi ya hatua kwa siku. Wakati ambao washiriki walilala na kuamka ulirekodiwa ili kuruhusu marekebisho ya vipimo vya cortisol.
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     Vipimo vya misuli ya mifupa
    </title>
    <sec id="Sec16">
     <title>
      Respirometry ya misuli ya mifupa
     </title>
     <p id="Par28">
      Kazi ya mitochondria ilipimwa katika nyuzi zilizopenyezwa kama ilivyoelezwa hapo awali
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      . Vikundi vidogo vya nyuzi mpya zilizotengwa zilipenyezwa na 50 µg mL saponin kwa dakika 20 katika 4 °C katika suluhisho lenye (katika mM) CaEGTA (2.8), EGTA (7.2), ATP (5.8), MgCl
      <sub>
       2
      </sub>
      (6.6), taurine (20), phosphocreatine (15), imidazole (20), DTT (0.5) na MES (50) (pH 7.1). Tishu zilioshwa katika suluhisho la kupumua lenye EGTA (0.5), MgCl
      <sub>
       2
      </sub>
      (3), K-lactobionate (60), taurine (20), KH
      <sub>
       2
      </sub>
      PO
      <sub>
       4
      </sub>
      (10), HEPES (20), sucrose (110) na 1 g L BSA isiyo na asidi ya mafuta (pH 7.1), zikakauka haraka, zikapimwa uzito na kuhamishiwa kwenye respirometer (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria) katika suluhisho la kupumua katika 37 °C. Mkazo wa oksijeni ulidumishwa juu ya 300 μM wakati wote wa jaribio ili kuepuka vikwazo katika usambazaji wa oksijeni. Kupumua kwa msingi kulipimwa kabla ya kuongeza substrates na kuliondolewa kutoka kwa thamani zote zilizofuata. Kupumua kwa kuvuja kulipimwa baada ya kuongeza sodium glutamate (10 mM), sodium malate (0.5 mM), na sodium pyruvate (5 mM). Kupumua kwa NADH (Complex I)-kulikopimwa baada ya kuongeza 5 mM ADP, na 10 μM cytochrome c ili kuthibitisha kutokuwepo kwa uharibifu wa utando wa nje wa mitochondria. Uwezo wa juu wa oksidishaji, na pembejeo ya wakati mmoja kupitia NADH na kupumua kwa succinate, ulipimwa baada ya kuongeza 10 mM succinate. Kupumua kwa kiwango cha juu kisichounganishwa kulipimwa kupitia titration ya carbonylcyanide-4-trifluoro-methoxyphenylhydrazone (FCCP) katika hatua za 0.5 µM hadi hakuna ongezeko zaidi la matumizi ya oksijeni lilipoonekana. Kupumua kwa succinate kulipimwa baada ya kuzuia Complex I ya mitochondria na 0.5 μM rotenone. Vipimo viwili kwa sampuli vilifanywa kwa wakati mmoja, na matokeo yalilinganishwa. Thamani za kupumua zilinormalishwa kwa uzito wa mvua na kuonyeshwa katika pmol O
      <sub>
       2
      </sub>
      ·s mg
      <sup/>
      . Uwiano kadhaa ulipimwa baadaye, yaani uwiano wa udhibiti wa mfumo wa usafirishaji wa elektroni/ufosforasi ya oksidishaji (
      <inline-formula id="IEq1">
       <alternatives>
        <math id="IEq1_Math" xmlns="http://www.w3.org/1998/Math/MathML">
         <mfrac>
          <mrow>
           <mi mathvariant="normal">
            OxPhos
           </mi>
          </mrow>
          <mrow>
           <mi mathvariant="normal">
            ETS
           </mi>
          </mrow>
         </mfrac>
        </math>
        <tex-math id="IEq1_TeX">
         \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{{\rm {OxPhos}}}}{{{\rm {ETS}}}}$$\end{document}
        </tex-math>
        <inline-graphic href="41467_2023_44432_Article_IEq1.gif" mime-subtype="GIF" specific-use="web"/>
       </alternatives>
      </inline-formula>
      ), ufanisi wa udhibiti wa mfumo wa usafirishaji wa elektroni/ufosforasi ya oksidishaji
      <inline-formula id="IEq2">
       <alternatives>
        <math id="IEq2_Math" xmlns="http://www.w3.org/1998/Math/MathML">
         <mrow>
          <mo>
           (
          </mo>
          <mrow>
           <mfrac>
            <mrow>
             <mi mathvariant="normal">
              ETS
             </mi>
             <mo>
              −
             </mo>
             <mi mathvariant="normal">
              OxPhos
             </mi>
            </mrow>
            <mrow>
             <mi mathvariant="normal">
              ETS
             </mi>
            </mrow>
           </mfrac>
          </mrow>
          <mo>
           )
          </mo>
         </mrow>
        </math>
        <tex-math id="IEq2_TeX">
         \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$(\frac{{{\rm {ETS}}}-{{\rm {OxPhos}}}}{{{\rm {ETS}}}})$$\end{document}
        </tex-math>
        <inline-graphic href="41467_2023_44432_Article_IEq2.gif" mime-subtype="GIF" specific-use="web"/>
       </alternatives>
      </inline-formula>
      , na ufanisi wa kuunganisha kibiokemikali (
      <inline-formula id="IEq3">
       <alternatives>
        <math id="IEq3_Math" xmlns="http://www.w3.org/1998/Math/MathML">
         <mfrac>
          <mrow>
           <mi mathvariant="normal">
            ETS
           </mi>
           <mo>
            −
           </mo>
           <mi mathvariant="normal">
            Leak
           </mi>
          </mrow>
          <mrow>
           <mi mathvariant="normal">
            ETS
           </mi>
          </mrow>
         </mfrac>
        </math>
        <tex-math id="IEq3_TeX">
         \documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{{\rm {ETS}}}-{{\rm {Leak}}}}{{{\rm {ETS}}}}$$\end{document}
        </tex-math>
        <inline-graphic href="41467_2023_44432_Article_IEq3.gif" mime-subtype="GIF" specific-use="web"/>
       </alternatives>
      </inline-formula>
      )
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
       ,
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec17">
     <title>
      Immuno-histochemistry
     </title>
     <p id="Par29">
      Ili kuona umbo la nyuzi za misuli, dalili za patholojia, na uwepo wa amana zenye amyloid na chembe za virusi, (immuno-)histochemistry ilifanywa kwenye sehemu zenye unene wa 10 µm kutoka kwa biopsi za misuli ya vastus lateralis. Maelezo kuhusu upunguzaji na wauzaji yanaweza kupatikana katika Jedwali
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      <sup/>
      . Atrophy na necrosis katika uchanganuzi wa hematoxylin na eosin zilipimwa na wataalamu wawili wa patholojia ambao hawakujua mgawanyo wa kikundi. Uingizaji wa seli za T (CD3), seli za B (CD20) na macrophages (CD68) katika misuli ya mifupa ulipimwa kwa chanya au hasi (Jedwali
      <xref ref-type="table" rid="Tab3">
       3
      </xref>
      <sup/>
      .
      <table-wrap id="Tab3">
       <label>
        Jedwali 3
       </label>
       <caption xml:lang="en">
        <p>
         Maelezo kuhusu kingamwili, pamoja na upunguzaji na wauzaji
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           <p>
            Kigezo
           </p>
          </th>
          <th>
           <p>
            Kingamwili, upunguzaji, muuzaji
           </p>
          </th>
          <th>
           <p>
            Kingamwili ya pili (upunguzaji), muuzaji
           </p>
          </th>
          <th>
           <p>
            RRID
           </p>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           <p>
            Aina ya nyuzi za misuli
           </p>
          </td>
          <td>
           <p>
            BA-D5 (MHC-I), 1 μg/ml, DSHB
           </p>
           <p>
            SC-71 (MHC-IIA), 1 μg/ml, DSHB
           </p>
           <p>
            6H1 (MHC-IIX) 5 μg/ml, DSHB (dakika 60)
           </p>
           <p>
            WGA 350, 1:25, TMO W11263 (dakika 30)
           </p>
           <p>
            MHCI (BA-D5), 1 μg/ml, DSHBMHC IIA (SC-71), 1 μg/ml, DSHB
           </p>
           <p>
            MHC IIX (6H1), 5 μg/ml, DSHB (dakika 60)
           </p>
           <p>
            WGA 350, 1:25, TMO W11263 (dakika 30)
           </p>
          </td>
          <td>
           <p>
            Goat-anti-mouse IgG2b 555, 1:1000, Invitrogen A21147; Goat anti-mouse IgG1 647, 1:1000, Invitrogen A21240; Goat anti-mouse IgM 488, 1:1000, Invitrogen A21042 (dakika 60)
           </p>
          </td>
          <td>
           <p>
            AB_2235587AB_2147165; AB_1157897;
           </p>
           <p>
            AB_2535783; AB_2535809; AB_2535711
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            Amiloidi-
           </p>
           <p>
            zilizo na amana
           </p>
          </td>
          <td>
           <p>
            Thioflavin T (50 μM hisa), 1:10, Sigma-Aldrich (dakika 30)
           </p>
           <p>
            WGA 555, 1:25, TMO W32464 (dakika 30)
           </p>
          </td>
          <td>
           <p>
            N.A.
           </p>
          </td>
          <td/>
         </tr>
         <tr>
          <td>
           <p>
            Selimundu za endotheliamu
           </p>
          </td>
          <td>
           <p>
            CD31, IgG1 panya, 1:50, Abcam ab9498
           </p>
           <p>
            (kuachwa usiku kucha)
           </p>
           <p>
            WGA 350, 1:25, TMO W11263 (dakika 30)
           </p>
          </td>
          <td>
           <p>
            Goat anti-mouse IgG1 647, 1:200, Invitrogen A21240
           </p>
           <p>
            (dakika 60)
           </p>
          </td>
          <td>
           <p>
            AB_726362
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            Selimundu za endotheliamu
           </p>
          </td>
          <td>
           <p>
            Biotinylated UEA-1, 1:100,
           </p>
           <p>
            B-1065, Maabara ya Vector
           </p>
           <p>
            (dakika 30)
           </p>
          </td>
          <td>
           <p>
            Vectastain Elite ABC Kit PK-6100, Maabara ya Vector (dakika 30);
           </p>
           <p>
            ImmPACT™ AMEC Red Peroxidase Substrate SK-4285, Maabara ya Vector (dakika 10)
           </p>
          </td>
          <td>
           <p>
            AB_2336766
           </p>
           <p>
            AB_2336819
           </p>
           <p>
            AB_2336519
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            Chombo cha lymphatic
           </p>
          </td>
          <td>
           <p>
            LYVE1, IgG sungura, 1:50 Abcam 10278
           </p>
           <p>
            (kuachwa usiku kucha)
           </p>
           <p>
            WGA 350, 1:25, TMO W11263 (dakika 30)
           </p>
          </td>
          <td>
           <p>
            Goat anti-rabbit IgG 647, 1:200, Invitrogen A32733
           </p>
           <p>
            (dakika 60)
           </p>
          </td>
          <td>
           <p>
            AB_881387
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            Protini ya nucleocapsid ya SARS-CoV-2
           </p>
          </td>
          <td>
           <p>
            Kingamwili ya Nucleocapsid ya SARS-CoV-2, Sungura PAb, Antigen Affinity Purified, 1:500; SinoBiological (dakika 60)
           </p>
           <p>
            WGA 555, 1:25, TMO W32464 (dakika 30)
           </p>
          </td>
          <td>
           <p>
            Alexa fluor goat-anti rabbit IgG 488 1:500, Invitrogen A27034 (dakika 60)
           </p>
          </td>
          <td>
           <p>
            AB_2892769
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            CD3
           </p>
          </td>
          <td>
           <p>
            SP7 (sungura moab), 1:200, Thermo Sc. Rm-9107-S
           </p>
          </td>
          <td/>
          <td>
           <p>
            AB_149924
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            CD68
           </p>
          </td>
          <td>
           <p>
            PG-M1 IgG 3, 1:200, DAKO M0876
           </p>
          </td>
          <td/>
          <td>
           <p>
            AB_2074844
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            CD20
           </p>
          </td>
          <td>
           <p>
            L26 IgG 2a, 1:1000,DAKO/M0755
           </p>
          </td>
          <td/>
          <td>
           <p>
            AB_2282030
           </p>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         <italic>
          RRID
         </italic>
         vitambulisho vya rasilimali za utafiti.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <sec id="Sec18">
     <title>
      Muundo wa aina ya nyuzi
     </title>
     <p id="Par30">
      Kiwango na ukubwa wa aina ya nyuzi za misuli ya mifupa vilipimwa kwa kutumia mbinu za immunofluorescence kwa kutumia kingamwili za msingi dhidi ya myosin heavy chain (MHC) I (BA-D5), MHC II (SC-71), na MHC IIx (6H1)
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
      </sup>
      . Udhibiti hasi, bila kingamwili ya msingi, ulijumuishwa kwa marekebisho ya msingi. Kwanza, sehemu zilikaushwa hewani kwa dakika 10 na kisha kuzuiwa na 10% seramu ya mbuzi wa kawaida (NGS) kwa dakika 60. Baadaye, slaidi zilioshwa mara 3 kwa dakika 5 kila moja katika 1x phosphate-buffered saline (PBS) na kuingizwa na kingamwili za msingi kwa dakika 60 katika joto la kawaida. Tena, slaidi zilioshwa na kisha kuingizwa na kingamwili za sekondari kwa dakika 60 gizani katika joto la kawaida. Mara nyingine tena, hatua ya kuosha ilifanywa na kisha kuingizwa kwa slaidi na Wheat Germ Agglutinin (WGA) kwa dakika 30 gizani katika joto la kawaida, ikifuatiwa na hatua ya mwisho ya kuosha na kuweka sehemu na vifuniko kwa kutumia Vectashield Vibrance. Uchambuzi ulifanywa na ImageJ na Sandia Matlab AnalysiS Hierarchy (SMASH) Toolbox (toleo la 1.0) katika Matlab (toleo la 2022a). Usambazaji wa aina ya nyuzi ulionyeshwa kwa kutumia mbinu mbili: kwanza, kwa kuhesabu asilimia ya nyuzi zinazotoa kila MHC ikilinganishwa na jumla ya nyuzi zilizopo katika sehemu ya misuli. Hii iliruhusu utofautishaji kati ya nyuzi zinazotoa MHC-I na MHC-IIa, MHC-IIa pekee, na MHC-IIx na MHC-IIa. Pili, usambazaji wa nyuzi ulionyeshwa kama eneo la msalaba linalochukuliwa na kila aina ya nyuzi kama asilimia ya eneo la msalaba wa nyuzi zote. Hii iliruhusu upimaji wa hypertrophy/atrophy inayoweza kutokea na utoaji wa MHC fulani.
     </p>
    </sec>
    <sec id="Sec19">
     <title>
      Shughuli ya succinate dehydrogenase
     </title>
     <p id="Par31">
      Sehemu zilitiwa rangi kwa ajili ya shughuli ya succinate dehydrogenase (SDH), ambayo ilitumika kama kiashiria cha wingi wa mitochondria, kama ilivyoelezwa hapo awali
      <sup>
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
      </sup>
      . Mara baada ya kukatwa, sehemu zilikaushwa hewani kwa dakika 15 na kisha kuzamishwa katika suluhisho lililopashwa moto (37 °C) lenye sodium phosphate buffer (0.1 M, pH 7.6), sodium succinate (0.2 M), sodium azide (14 mM) na tetranitro blue tetrazolium (TNBT, 0.55 mM, Sigma) kwa dakika 20 gizani, na mmenyuko ulisimamishwa kwa mfiduo mfupi wa HCl (0.01 M) kabla ya sehemu kuoshwa na kuwekwa na glycerin-gelatin. Sehemu ziliwekwa katika 4 °C na kupigwa picha ndani ya siku kumi. Shughuli ya SDH iliyopimwa ilipatikana kwa kuainisha nyuzi za misuli ya mifupa moja moja na upitishaji wa mwanga ulipimwa kwa kutumia ImageJ (NIH, Bethesda, USA). Thamani zilionyeshwa kama Δ
      <italic>
       A
      </italic>
      <sub>
       660
      </sub>
      kwa unene wa tishu ya µm kwa sekunde ya muda wa kutia rangi (Δ
      <italic>
       A
      </italic>
      <sub>
       660
      </sub>
      µm s)
      <sup/>
      .
     </p>
    </sec>
    <sec id="Sec20">
     <title>
      Capillarization
     </title>
     <p id="Par32">
      Capillarization ilipimwa kwa kutia rangi kwa Ulex Europaeus Agglutinin 1 lectin (UEA-1)
      <sup>
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      . Sehemu zilikaushwa hewani kwa dakika 10 na kufungiwa katika acetone baridi ya barafu (−20 °C) kwa dakika 15. Baadaye, slaidi zilioshwa mara 3 kwa dakika 2 katika PBS na kuzuiwa na 1% album ya seramu ya ng'ombe kwa dakika 30. Baada ya hapo, slaidi ziliingizwa na UEA-1 kwa dakika 30 katika joto la kawaida, ikifuatiwa na hatua za kuosha na kuingizwa na Vectastain Elite ABC kit kwa dakika 30 katika joto la kawaida. Baada ya kuosha, kuingizwa na substrate ya Red Peroxidase kwa dakika 10 katika joto la kawaida kulifanywa, kuoshwa, na sehemu ziliwekwa na glycerin-gelatin (iliyopashwa moto katika 37 °C). Uwiano wa capillary-to-fiber (C/F) na wingi wa capillary (CD) kwa capillaries kwa mm ya tishu ya misuli ulipimwa katika ImageJ
      <sup/>
      .
     </p>
    </sec>
    <sec id="Sec21">
     <title>
      Amiloidi zinazoshikilia amana
     </title>
     <p id="Par33">
      Ili kuonyesha uwepo wa amana zenye amyloid, sehemu za misuli ya mifupa zilifichuliwa kwa 5 μM Thioflavin T (ThT). Sehemu za misuli zilizo na amana nyingi zaidi za amyloid ziliwekwa rangi zaidi na ThT pamoja na kingamwili maalum ya CD31 ili kuonyesha seli za endotheliamu na kingamwili maalum ya LYVE-1 ili kuonyesha mishipa ya limfu. Kwanza, sehemu zilikauka hewani kwa dakika 10 kisha zikafanywa imara kwa 4% paraformaldehyde (PFA) kwa dakika 5 tu kwa ajili ya upakaji rangi mara mbili. Baadaye, slaidi zilioshwa mara 3 kwa dakika 5 kila moja katika PBS Tween (PBST) na kuzuiwa na 10% NGS kwa dakika 60. Kisha, hatua ya kuosha ilikamilishwa tena, ikifuatiwa na kuweka kingamwili ya msingi (ama CD31 au LYVE1) katika 0.1% bovine serum albumin (BSA) katika PBS usiku kucha kwa 4 °C. Udhibiti hasi, bila kingamwili ya msingi, ulijumuishwa. Slaidi zilioshwa katika PBST na kisha kuwekwa na kingamwili ya sekondari kwa dakika 60 gizani katika joto la kawaida. Baadaye, hatua ya kuosha ilifanywa na ikafuatiwa na kuweka ThT katika 0.1% BSA katika PBS kwa dakika 30, ikifuatiwa na hatua nyingine ya kuosha. Mwisho, kuweka slaidi na WGA kwa dakika 30 gizani katika joto la kawaida, ikifuatiwa na hatua ya mwisho ya kuosha na kuweka sehemu na vifuniko kwa kutumia Vectashield Vibrance.
     </p>
    </sec>
    <sec id="Sec22">
     <title>
      SARS-CoV-2
     </title>
     <p id="Par34">
      Ili kubaini uwepo wa virusi katika seli za misuli, sehemu ziliwekwa rangi kwa SARS-CoV-2
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Upakaji rangi ulianza kwa kukausha sehemu hewani kwa dakika 10, ikifuatiwa na hatua ya kuzuia na 10% NGS kwa dakika 60. Hatua ya kuosha iliyojumuisha vipindi vya dakika 5 mara 3 katika 1× PBS ilifuata, baada ya hapo sehemu ziliwekwa na kingamwili ya msingi anti-N kwa dakika 60 katika joto la kawaida. Hatua nyingine ya kuosha ilifuata, na kisha kuweka kingamwili ya sekondari kwa dakika 60 gizani katika joto la kawaida. Baadaye, hatua ya kuosha ilifanywa tena, ikifuatiwa na kuweka WGA kwa dakika 30 gizani katika joto la kawaida. Sehemu zilioshwa mara ya mwisho na kuwekwa na kifuniko kwa kutumia Vectashield hard set na DAPI.
     </p>
    </sec>
    <sec id="Sec23">
     <title>
      Upatikanaji wa picha
     </title>
     <p id="Par35">
      Slaidi zilikauka usiku kucha kwa 4 °C kabla ya kupiga picha. Picha za aina ya nyuzi na uchambuzi wa capillarization zilipigwa kwa kukuza ×20 na VS200 Research Slide Scanner (Olympus) kwa kutumia Slideview 5.0. Picha za SDH zilipigwa na darubini ya DMRB (Leica, Wetzlar) kwa kutumia kamera ya CCD, vichujio vya kijivu vilivyopimwa, na mlinganyo wa kibinafsi wa kalibrasha kwa 660 nm. Picha za upakaji rangi wa mchanganyiko wa ThT zilipigwa kwa kukuza ×40 kwa kutumia darubini ya fluorescence (Axiovert 200M; Zeiss) na programu ya usindikaji picha Slidebook 5.0. Takriban picha kumi na tano zilipigwa kwa sampuli, na picha 5 kwa kila sehemu ya slaidi. Picha zote zilipitiwa kwa mkono ili kuondoa zile zilizo na maeneo yasiyo na umakini, mabaki, na maeneo makubwa ya tishu za kuunganisha. Marekebisho ya usuli kwa CD31 na LYVE-1 yalifanywa kulingana na udhibiti hasi. Kwa ThT, marekebisho ya usuli yalifanywa kwa kuweka kizingiti kwa udhibiti hasi kwa 99.0%. Mifano yote ya kawaida ilifutwa na Huygens Professional toleo la 22.40 (Scientific Volume Imaging, Uholanzi,
      <ext-link ext-link-type="uri" href="http://svi.nl">
       http://svi.nl
      </ext-link>
      ), kwa kutumia algorithimu ya CMLE, na Acuity: −90, marudio 90, na mipangilio ya msingi kwa SNR na thamani za usuli. Kwa upakaji rangi wa ThT, marekebisho ya usuli yalifanywa kwa mkono.
     </p>
    </sec>
    <sec id="Sec24">
     <title>
      Metabolomics
     </title>
     <p id="Par36">
      Metabolomics ilifanywa kwenye biopsi za misuli ya mifupa na sampuli za damu ya vena kama ilivyoelezwa hapo awali, na marekebisho madogo
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
       ,
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Njia yetu ya metabolomics imeundwa mahsusi kuchambua metaboliti muhimu za polar za njia za kimetaboliki za msingi kwa ujasiri wa hali ya juu, badala ya njia pana isiyolengwa ambapo utambuzi ni wa kutatanisha zaidi. Vipimo vya ionization chanya na hasi vilifanywa kando. Katika tube ya 2 mL, yenye ama 20 µL ya plasma au wastani wa 3.2 mg ya tishu za misuli zilizokaushwa, kiasi kifuatacho cha kiwango cha ndani kilichoyeyushwa katika maji kiliongezwa kwa kila sampuli: adenosine-N
      <sub>
       5
      </sub>
      -monophosphate (5 nmol), adenosine-N
      <sub>
       5
      </sub>
      -triphosphate (5 nmol), D
      <sub>
       4
      </sub>
      -alanine (0.5 nmol), D
      <sub>
       7
      </sub>
      -arginine (0.5 nmol), D
      <sub>
       3
      </sub>
      -aspartic acid (0.5 nmol), D
      <sub>
       3
      </sub>
      -carnitine (0.5 nmol), D
      <sub>
       4
      </sub>
      -citric acid (0.5 nmol), C
      <sub>
       1
      </sub>
      -citrulline (0.5 nmol), C
      <sub>
       6
      </sub>
      -fructose-1,6-diphosphate (1 nmol), C
      <sub>
       2
      </sub>
      -glycine (5 nmol), guanosine-N
      <sub>
       5
      </sub>
      -monophosphate (5 nmol), guanosine-N
      <sub>
       5
      </sub>
      -triphosphate (5 nmol), C
      <sub>
       6
      </sub>
      -glucose (10 nmol), C
      <sub>
       6
      </sub>
      -glucose-6-phosphate (1 nmol), D
      <sub>
       3
      </sub>
      -glutamic acid (0.5 nmol), D
      <sub>
       5
      </sub>
      -glutamine (0.5 nmol), D
      <sub>
       5
      </sub>
      -glutathione (1 nmol), C
      <sub>
       6
      </sub>
      -isoleucine (0.5 nmol), D
      <sub>
       3
      </sub>
      -lactic acid (1 nmol), D
      <sub>
       3
      </sub>
      -leucine (0.5 nmol), D
      <sub>
       4
      </sub>
      -lysine (0.5 nmol), D
      <sub>
       3
      </sub>
      -methionine (0.5 nmol), D
      <sub>
       6
      </sub>
      -ornithine (0.5 nmol), D
      <sub>
       5
      </sub>
      -phenylalanine (0.5 nmol), D
      <sub>
       7
      </sub>
      -proline (0.5 nmol), C
      <sub>
       3
      </sub>
      -pyruvate (0.5 nmol), D
      <sub>
       3
      </sub>
      -serine (0.5 nmol), D
      <sub>
       6
      </sub>
      -succinic acid (0.5 nmol), D
      <sub>
       4
      </sub>
      -thymine (1 nmol), D
      <sub>
       5
      </sub>
      -tryptophan (0.5 nmol), D
      <sub>
       4
      </sub>
      -tyrosine (0.5 nmol), D
      <sub>
       8
      </sub>
      -valine (0.5 nmol). Baadaye, vimumunyisho viliongezwa kufikia jumla ya ujazo wa 500 µL maji, 500 µL methanoli, na 1 mL klorofomu. Tishu za misuli zilihomogenishwa kabla ya kuongeza klorofomu kwa kutumia Qiagen TissueLyser II kwa dakika 5 kwa mara 30/s na shanga ya chuma cha pua ya Qiagen 5 mm katika kila tube. Sampuli zote zilichanganywa vizuri, kabla ya centrifugation kwa dakika 10 kwa 14,000 rpm
      <sup/>
      .
     </p>
     <p id="Par37">
      Tabaka la juu, lenye awamu ya polar, lilihamishiwa kwenye tube safi ya 1.5 mL na kukausha kwa kutumia mkusanyaji wa utupu kwa 60 °C. Sampuli zilizokaushwa zilirejeshwa katika 100 µL 6:4 (v/v) methanoli:maji. Metaboliti zilichambuliwa kwa kutumia mfumo wa Waters Acquity ultra-high performance liquid chromatography uliounganishwa na Bruker Impact II™ Ultra-High Resolution Qq-Time-Of-Flight mass spectrometer. Sampuli ziliwekwa kwa 12 °C wakati wa uchambuzi, na 5 µL ya kila sampuli ilidungwa. Utengano wa kromatografia ulifanyika kwa kutumia safu ya Merck Millipore SeQuant ZIC-cHILIC (PEEK 100 × 2.1 mm, ukubwa wa chembe 3 µm). Joto la safu lilishikiliwa kwa 30 °C. Awamu ya rununu ilijumuisha (A) 1:9 (v/v) acetonitrile:maji na (B) 9:1 (v/v) acetonitrile:maji, zote zikiwa na 5 mmol/L ammonium acetate. Kwa kutumia kiwango cha mtiririko wa 0.25 mL/min, gradient ya LC ilijumuisha: Kukaa kwa 100% ya Kimumunyisho B, 0–2 min; Kupanda hadi 54% ya Kimumunyisho B kwa 13.5 min; Kupanda hadi 0% ya Kimumunyisho B kwa 13.51 min; Kukaa kwa 0% ya Kimumunyisho B, 13.51–19 min; Kupanda hadi 100% B kwa 19.01 min; Kukaa kwa 100% ya Kimumunyisho B, 19.01–19.5 min. Usawazishaji wa safu ulifanywa kwa kuongeza kiwango cha mtiririko hadi 0.4 mL/min kwa 100% B 19.5–21 min. Data za MS zilipatikana kwa kutumia ionization hasi na chanya katika hali ya skani kamili juu ya safu ya
      <italic>
       m
      </italic>
      /
      <italic>
       z
      </italic>
      50–1200. Data zilichambuliwa kwa kutumia programu ya Bruker TASQ toleo la 2.1.22.3. Ukali wa metaboliti zote zilizoripotiwa ulirekebishwa kwa uzito wa tishu zilizokaushwa au ujazo wa plasma, pamoja na viwango vya ndani vilivyo na nyakati za kuhifadhi zinazolingana na majibu katika MS. Utambulisho wa metaboliti umejengwa juu ya mchanganyiko wa wingi sahihi, nyakati za kuhifadhi (za jamaa), data za uhamaji wa ion na spectra za kugawanyika, ikilinganishwa na uchambuzi wa maktaba ya viwango. Vipimo vilivyo chini ya kikomo cha chini cha upimaji vilijazwa kama nusu ya thamani ya chini zaidi. Metaboliti ziliondolewa kwenye uchambuzi ikiwa zilikuwa na thamani zilizokosekana kwa zaidi ya 5% ya sampuli. Sampuli nne kutoka kwa metabolomics ya misuli ya mifupa ziliondolewa wakati wa udhibiti wa ubora.
     </p>
    </sec>
   </sec>
   <sec id="Sec25">
    <title>
     Vipimo vya damu ya vena
    </title>
    <sec id="Sec26">
     <title>
      Viwango vya homoni
     </title>
     <p id="Par38">
      Viwango vya cortisol, creatine kinase na creatine kinase-MB katika damu ya vena vilipimwa katika maabara ya kliniki ya Amsterdam UMC, na maelezo yanatolewa katika Jedwali
      <xref ref-type="table" rid="Tab4">
       4
      </xref>
      <sup/>
      .
      <table-wrap id="Tab4">
       <label>
        Jedwali 4
       </label>
       <caption xml:lang="en">
        <p>
         Maelezo kuhusu mbinu za viwango vya damu ya mshipa
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           <p>
            Kigezo
           </p>
          </th>
          <th>
           <p>
            Vifaa
           </p>
          </th>
          <th>
           <p>
            Mbinu
           </p>
          </th>
          <th>
           <p>
            Mipaka ya marejeo
           </p>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           <p>
            Cortisol
           </p>
          </td>
          <td>
           <p>
            Roche cobas C8000
           </p>
          </td>
          <td>
           <p>
            Immunoassay ya Electro-chemiluminescence “ECLIA” Roche Diagnostics
           </p>
          </td>
          <td>
           <p>
            250–650 nmol/L
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            Creatine kinase
           </p>
          </td>
          <td>
           <p>
            c702 Roche diagnostics
           </p>
          </td>
          <td>
           <p>
            NAC-activated, 37 °C Roche Diagnostics
           </p>
          </td>
          <td>
           <p>
            Mwanaume &lt; 171 U/L
           </p>
           <p>
            Mwanamke &lt; 145 U/L
           </p>
          </td>
         </tr>
         <tr>
          <td>
           <p>
            Creatine kinase-MB
           </p>
          </td>
          <td>
           <p>
            e602
           </p>
           <p>
            Roche
           </p>
           <p>
            Diagnostics
           </p>
          </td>
          <td>
           <p>
            Immunoassay ya sandwich yenye alama ya enzyme
           </p>
           <p>
            Roche Diagnostics
           </p>
          </td>
          <td>
           <p>
            &lt;4 μg/L
           </p>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec id="Sec27">
     <title>
      DNA ya mitochondrial inayozunguka
     </title>
     <p id="Par39">
      Vipimo vya DNA ya mitochondria (mtDNA) vilifanywa kwa kutumia sampuli za plasma. DNA ilitengwa kulingana na kifaa cha BIOKE NucleoSpinⓇ Tissue. Kwa ufupi, plasma ilitenganishwa kutoka kwa damu iliyokusanywa kwenye chupa zilizopakwa ethylenediaminetetraacetic acid kwa kuzungusha kwa 1500×
      <italic>
       g
      </italic>
      kwa dakika 10. Baadaye, 50 µL ya plasma ilipunguzwa katika suluhisho lenye 150 µL PBS, 25 µL proteinase K, na 200 µL Buffer B3. Baada ya kuweka kwenye joto la 70 °C kwa dakika 15, 210 µL ya ethanoli 96% iliongezwa kwenye suluhisho na kuzungushwa kwa dakika 1 kwa 11,000×
      <italic>
       g
      </italic>
      , ambapo suluhisho lilipita kwenye safu ya utando wa silika. Safu hiyo iliwekwa kwenye chupa mpya ya kukusanya, ikasafishwa na 500 µL Buffer BW na kuzungushwa kwa dakika 1 kwa 11,000×
      <italic>
       g
      </italic>
      <sup/>
      . Hii ilifuatwa na kuoshwa na 600 µL ya buffer B5 na kuzungushwa tena kwa dakika 1 kwa 11,000×
      <italic>
       g
      </italic>
      <sup/>
      . Mwisho, 100 µL ya buffer BE iliongezwa, ikawekwa kwa dakika 3, na kuzungushwa mara ya mwisho kwa dakika 1 kwa 11,000×
      <italic>
       g
      </italic>
      ili kutoa DNA iliyotengwa katika suluhisho. Vianzilishi vya ND1 na ND6 mtDNA vilitumika kuhesabu idadi ya nakala za mtDNA, kwa kutumia
      <monospace>
       ΔΔ
      </monospace>
      Ct-method. Kila kisima kilikuwa na 2 µL ya mtDNA, 3 µL ya mchanganyiko wa vianzilishi, na 5 µl ya Power Up SYBR Green Master mix. Baadaye, qPCR kwa duplo ilifanywa kwa kutumia QuantStudio 3 real-time PCR ili kupima viwango vya mtDNA kulingana na rejea ya nyuklia. S. Thamani zilinormalishwa kwa wakati wa kwanza
      <sup>
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      .
     </p>
    </sec>
   </sec>
   <sec id="Sec28">
    <title>
     Uchambuzi wa takwimu
    </title>
    <p id="Par40">
     Usambazaji ulitathminiwa kwa histograms na vipimo vya Shapiro–Wilk. Thamani za kategoria zimeonyeshwa kwa nambari kamili na asilimia kwenye mabano. Vigezo vya kiasi vya parametric vimewasilishwa kama wastani ± mkengeuko wa kawaida (SD), na vigezo vya kiasi visivyo vya parametric vimewasilishwa kama wastani na viwango vya kati (IQR; asilimia 25 na 75). Mchoro wa sanduku unaonyeshwa na wastani na IQR (asilimia 25 na 75) isipokuwa kama ilivyoainishwa vinginevyo. Pointi zote za mtu binafsi zinawakilisha mshiriki.
    </p>
    <p id="Par41">
     Data zisizo na usambazaji wa kawaida ziligeuzwa kwa kutumia mabadiliko ya Box-Cox ili kupata usambazaji wa kawaida kwa uchambuzi wa takwimu
     <sup>
      <xref ref-type="bibr" rid="CR66">
       66
      </xref>
     </sup>
     . Data za kategoria zilichambuliwa kwa kutumia kipimo sahihi cha Fisher. Data endelevu za parametric zilichambuliwa kwa kutumia
     <italic>
      t
     </italic>
     -test au uchambuzi wa tofauti, na upimaji wa baada ya Tukey HSD, inapofaa. Data endelevu zisizo za parametric zilichambuliwa kwa kutumia kipimo cha Mann–Whitney
     <italic>
      U
     </italic>
     , kipimo cha Kruskal–Wallis
     <italic>
      H
     </italic>
     , au kipimo cha Kruskal–Wallis cha jozi na marekebisho ya Benjamini–Hochberg (BH) inapofaa. Mahusiano yalichambuliwa kwa kutumia mgawo wa uhusiano wa Pearson kwa mahusiano ya mstari na mgawo wa uhusiano wa Spearman kwa mahusiano yasiyo ya mstari. Viwango vya uhusiano vililinganishwa kwa kutumia kifurushi cha R
     <italic>
      cocor
     </italic>
     <sup>
      <xref ref-type="bibr" rid="CR67">
       67
      </xref>
     </sup>
     . Data za kategoria za muda mrefu zilichambuliwa kwa kutumia usajili wa kimantiki na Wakati (msingi na siku 1 baada ya mazoezi) kama kigezo. Data endelevu za parametric za muda mrefu na metabolomics zilichambuliwa kwa kutumia mfano wa mchanganyiko wa mstari wa jumla na wakati (msingi, siku 1, na wiki 1 baada ya mazoezi), kikundi na athari za mwingiliano. Data za metabolomics zilirekebishwa na marekebisho ya BH ndani ya njia ya metabolome iliyowekwa awali. Ulinganisho wa baada ya muda wa data za muda mrefu ulifanywa, ikiwa neno la mwingiliano lilikuwa muhimu, kwa kutumia Tofauti za Wastani wa Kidhahania kwa kutumia mbinu za kifurushi cha R
     <italic>
      emmeans
     </italic>
     na marekebisho ya BH. Uchambuzi wa data endelevu zisizo za parametric za muda mrefu ulifanywa kwa kulinganisha delta (
     <italic>
      Δ
     </italic>
     ) kati ya vipindi vya wakati. Data za muda mrefu za metabolomic zilionyeshwa na ukubwa wa athari uliohesabiwa kwa kutumia Hedges’
     <italic>
      g
     </italic>
     <sup>
      <xref ref-type="bibr" rid="CR68">
       68
      </xref>
      <xref ref-type="bibr" rid="CR69">
       69
      </xref>
     </sup>
     .
     <italic>
      p
     </italic>
     -values &lt; 0.05 (pande mbili) zilizingatiwa kuwa na umuhimu wa takwimu. Data zote zilichambuliwa kwa kutumia R studio iliyojengwa chini ya R toleo 4.0.3 (R Core Team 2013, Vienna, Austria).
    </p>
   </sec>
   <sec id="Sec29">
    <title>
     Muhtasari wa ripoti
    </title>
    <p id="Par42">
     Maelezo zaidi kuhusu muundo wa utafiti yanapatikana katika
     <xref ref-type="supplementary-material" rid="MOESM3">
      Muhtasari wa Kuripoti wa Nature Portfolio
     </xref>
     uliounganishwa na makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Tunawashukuru sana washiriki wote kwa muda wao na kujitolea kushiriki katika utafiti huu. Pia tungependa kuwashukuru wafanyakazi wote wa kliniki ya wagonjwa wa nje ya baada ya COVID ya Amsterdam UMC, hasa, Dkt. Mooij-Kalverda na Huismans, kwa msaada wao wakati wa utafiti huu. Tunatambua pia msaada wa Dkt. Eric Voorn katika upatikanaji wa data ya vipimo vya shughuli za mwili, Onno van Driel katika uchambuzi wa usambazaji wa aina ya nyuzi, na Jos de Koning katika kusaidia ukusanyaji wa data za mazoezi. Utafiti huu ulifadhiliwa na ufadhili wa kibinafsi, Ushirikiano wa Utafiti Unaosimamiwa na Wagonjwa kwa COVID ndefu (Grant ID: C1, [MvV]), Mfuko wa Talud kwa Mfuko wa Utafiti wa Corona wa Amsterdam UMC [WWJ], AMC Foundation [MvV], VU Foundation [RCIW], ZonMw Onderzoeksprogramma ME/CVS [RCIW], na Mpango wa Ramsay Grant wa 2022 [RCIW].
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Mchango wa waandishi
   </title>
   <p>
    B.A., B.C., M.v.V., na R.W. wamechangia sana katika dhana, muundo, upatikanaji wa kifedha, uchambuzi, na tafsiri ya data, uandishi wa kazi, na kurekebisha hati. R.G., T.K., E.B., W.N., na C.O. wamechangia sana katika dhana, muundo, uchambuzi, na tafsiri ya data, uandishi wa kazi, na kurekebisha sana hati. F.B., M.v.W., B.S., P.C., J.P., E.A., na W.J.W. wamechangia sana katika dhana, muundo, uchambuzi wa data, uandishi, na marekebisho ya hati. Waandishi wote wameidhinisha toleo lililowasilishwa na wanakubali kuwajibika binafsi kwa michango ya mwandishi mwenyewe na kuhakikisha kuwa maswali yanayohusiana na usahihi au uadilifu wa sehemu yoyote ya kazi, hata zile ambazo mwandishi hakuwa amehusika binafsi, yanachunguzwa ipasavyo, kutatuliwa, na suluhisho linaandikwa katika fasihi.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Mapitio ya rika
   </title>
   <sec id="FPar1">
    <title>
     Taarifa za mapitio ya rika
    </title>
    <p id="Par43">
     <italic>
      Nature Communications
     </italic>
     thanks Danilo Buonsenso, Michael Doumen, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa data
   </title>
   <p>
    The source data file is available below. The raw metabolomics data generated in this study have been deposited in the data publication platform of the Vrije University Amsterdam, with
    <ext-link ext-link-type="doi" xlink:href="10.48338/VU01-KPABVO">
     https://doi.org/10.48338/VU01-KPABVO
    </ext-link>
    . Metabolomics is available on MetaboLights (with study identification code: MTBLS9103).
    <xref ref-type="sec" rid="Sec31">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa msimbo
   </title>
   <p>
    R codes are available at
    <ext-link ext-link-type="doi" xlink:href="10.5281/zenodo.10171056">
     https://doi.org/10.5281/zenodo.10171056
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Maslahi yanayokinzana
    </title>
    <p id="Par44">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marejeo
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Davis
        </surname>
        <given-names>
         HE
        </given-names>
       </name>
       <name>
        <surname>
         Mccorkell
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Vogel
        </surname>
        <given-names>
         JM
        </given-names>
       </name>
       <name>
        <surname>
         Topol
        </surname>
        <given-names>
         EJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Long COVID: major findings, mechanisms and recommendations
      </article-title>
      <source>
       Nat. Rev. Microbiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       21
      </volume>
      <fpage>
       133
      </fpage>
      <lpage>
       146
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhtV2rtrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36639608
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9839201
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hickie
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study
      </article-title>
      <source>
       BMJ
      </source>
      <year>
       2006
      </year>
      <volume>
       333
      </volume>
      <fpage>
       575
      </fpage>
      <lpage>
       578
      </lpage>
      <pub-id pub-id-type="pmid">
       16950834
      </pub-id>
      <pub-id pub-id-type="pmcid">
       1569956
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ruiz-Pablos
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Paiva
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Montero-Mateo
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Garcia
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Zabaleta
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <fpage>
       4637
      </fpage>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ursinus
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study
      </article-title>
      <source>
       Lancet Reg. Health—Eur.
      </source>
      <year>
       2021
      </year>
      <volume>
       6
      </volume>
      <fpage>
       100142
      </fpage>
      <pub-id pub-id-type="pmid">
       34557833
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8454881
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1471.34013
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Herridge
        </surname>
        <given-names>
         MS
        </given-names>
       </name>
       <name>
        <surname>
         Azoulay
        </surname>
        <given-names>
         É
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Outcomes after critical illness
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       388
      </volume>
      <fpage>
       913
      </fpage>
      <lpage>
       924
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXlsVGrsLg%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36884324
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1536.60093
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Subramanian
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Symptoms and risk factors for long COVID in non-hospitalized adults
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1706
      </fpage>
      <lpage>
       1714
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvFGgtr%2FF
      </pub-id>
      <pub-id pub-id-type="pmid">
       35879616
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9388369
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1516.37116
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kedor
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       13
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13...21K
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kerkhoff
        </surname>
        <given-names>
         TJ
        </given-names>
       </name>
       <name>
        <surname>
         Charlton
        </surname>
        <given-names>
         BT
        </given-names>
       </name>
       <name>
        <surname>
         Appelman
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         van Vugt
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Wüst
        </surname>
        <given-names>
         RCI
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Post COVID‐19 condition: critical need for a clear definition and detailed pathophysiology
      </article-title>
      <source>
       J. Cachexia Sarcopenia Muscle
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       2754
      </fpage>
      <lpage>
       2756
      </lpage>
      <pub-id pub-id-type="pmid">
       36251474
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9745497
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chilunga
        </surname>
        <given-names>
         FP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Differences in incidence, nature of symptoms, and duration of long COVID among hospitalised migrant and non-migrant patients in the Netherlands: a retrospective cohort study
      </article-title>
      <source>
       Lancet Reg. Health Eur.
      </source>
      <year>
       2023
      </year>
      <volume>
       29
      </volume>
      <fpage>
       100630
      </fpage>
      <pub-id pub-id-type="pmid">
       37261215
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10079482
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1458.90393
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Al-Aly
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <name>
        <surname>
         Bowe
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Xie
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Long COVID after breakthrough SARS-CoV-2 infection
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1461
      </fpage>
      <lpage>
       1467
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xhtlyju7rE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35614233
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9307472
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="other">
      Klein, J. et al. Distinguishing features of Long COVID identified through immune profiling.
      <italic>
       Nature
      </italic>
      1–3 (2023)
      <ext-link ext-link-type="doi" xlink:href="10.1038/s41586-023-06651-y">
       https://doi.org/10.1038/s41586-023-06651-y
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hejbøl
        </surname>
        <given-names>
         EK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: evidence of skeletal muscle histopathology
      </article-title>
      <source>
       Eur. J. Neurol.
      </source>
      <year>
       2022
      </year>
      <volume>
       29
      </volume>
      <fpage>
       2832
      </fpage>
      <lpage>
       2841
      </lpage>
      <pub-id pub-id-type="pmid">
       35661354
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1517.35002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Pretorius
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin
      </article-title>
      <source>
       Cardiovasc. Diabetol.
      </source>
      <year>
       2021
      </year>
      <volume>
       20
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       18
      </lpage>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="other">
      Muri, J. et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course.
      <italic>
       Nat. Immunol.
      </italic>
      1–8 (2023)
      <ext-link ext-link-type="doi" xlink:href="10.1038/s41590-023-01445-w">
       https://doi.org/10.1038/s41590-023-01445-w
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         EY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Diverse functional autoantibodies in patients with COVID-19
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2021
      </year>
      <volume>
       595
      </volume>
      <fpage>
       283
      </fpage>
      <lpage>
       288
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021Natur.595..283W
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXht1yhsLzK
      </pub-id>
      <pub-id pub-id-type="pmid">
       34010947
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1488.16106
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kruger
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system
      </article-title>
      <source>
       Cardiovasc. Diabetol.
      </source>
      <year>
       2022
      </year>
      <volume>
       21
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       23
      </lpage>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Guo
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infection
      </article-title>
      <source>
       EBioMedicine
      </source>
      <year>
       2023
      </year>
      <volume>
       94
      </volume>
      <fpage>
       104729
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhs1Gitr%2FI
      </pub-id>
      <pub-id pub-id-type="pmid">
       37506544
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10406961
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1512.57019
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Soares
        </surname>
        <given-names>
         MN
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Skeletal muscle alterations in patients with acute Covid-19 and post-acute sequelae of Covid-19
      </article-title>
      <source>
       J. Cachexia Sarcopenia Muscle
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       11
      </fpage>
      <lpage>
       22
      </lpage>
      <pub-id pub-id-type="pmid">
       34997689
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8818659
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1511.35144
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization. Post COVID-19 condition (Long COVID).
      <ext-link ext-link-type="uri" xlink:href="https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition">
       https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition
      </ext-link>
      . (2023)
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Frésard
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in ‘long COVID’ patients with persistent dyspnoea
      </article-title>
      <source>
       BMJ Open Respir. Res.
      </source>
      <year>
       2022
      </year>
      <volume>
       9
      </volume>
      <fpage>
       e001126
      </fpage>
      <pub-id pub-id-type="pmid">
       35354589
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8968537
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1243.82039
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schwendinger
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Knaier
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Radtke
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Schmidt-Trucksäss
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Low cardiorespiratory fitness post-COVID-19: a narrative review
      </article-title>
      <source>
       Sports Med
      </source>
      <year>
       2023
      </year>
      <volume>
       53
      </volume>
      <fpage>
       51
      </fpage>
      <lpage>
       74
      </lpage>
      <pub-id pub-id-type="pmid">
       36115933
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Skjørten
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation
      </article-title>
      <source>
       Eur. Respir. J.
      </source>
      <year>
       2021
      </year>
      <volume>
       58
      </volume>
      <fpage>
       2100996
      </fpage>
      <pub-id pub-id-type="pmid">
       34210791
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8247555
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Singh
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing
      </article-title>
      <source>
       Chest
      </source>
      <year>
       2022
      </year>
      <volume>
       161
      </volume>
      <fpage>
       54
      </fpage>
      <lpage>
       63
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XntFGnsw%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       34389297
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Germain
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Plasma metabolomics reveals disrupted response and recovery following maximal exercise in myalgic encephalomyelitis/chronic fatigue syndrome
      </article-title>
      <source>
       JCI Insight
      </source>
      <year>
       2022
      </year>
      <volume>
       7
      </volume>
      <fpage>
       e157621
      </fpage>
      <pub-id pub-id-type="pmid">
       35358096
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9090259
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1510.35396
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         McGregor
        </surname>
        <given-names>
         NR
        </given-names>
       </name>
       <name>
        <surname>
         Armstrong
        </surname>
        <given-names>
         CW
        </given-names>
       </name>
       <name>
        <surname>
         Lewis
        </surname>
        <given-names>
         DP
        </given-names>
       </name>
       <name>
        <surname>
         Gooley
        </surname>
        <given-names>
         PR
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Post-exertional malaise is associated with hypermetabolism, hypoacetylation and purine metabolism deregulation in ME/CFS cases
      </article-title>
      <source>
       Diagnostics
      </source>
      <year>
       2019
      </year>
      <volume>
       9
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       11
      </lpage>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Missailidis
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An isolated complex V inefficiency and dysregulated mitochondrial function in immortalized lymphocytes from ME/CFS patients
      </article-title>
      <source>
       Int. J. Mol. Sci.
      </source>
      <year>
       2020
      </year>
      <volume>
       21
      </volume>
      <fpage>
       1074
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhslGmsL3L
      </pub-id>
      <pub-id pub-id-type="pmid">
       32041178
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7036826
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       02.0658.01
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wüst
        </surname>
        <given-names>
         RCI
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The antibiotic doxycycline impairs cardiac mitochondrial and contractile function
      </article-title>
      <source>
       Int. J. Mol. Sci.
      </source>
      <year>
       2021
      </year>
      <volume>
       22
      </volume>
      <fpage>
       4100
      </fpage>
      <pub-id pub-id-type="pmid">
       33921053
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8071362
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1471.93021
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Beloborodova
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils
      </article-title>
      <source>
       J. Biomed. Sci.
      </source>
      <year>
       2012
      </year>
      <volume>
       19
      </volume>
      <fpage>
       89
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3sXhsFWqsL8%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       23061754
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3503878
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Pedley
        </surname>
        <given-names>
         AM
        </given-names>
       </name>
       <name>
        <surname>
         Pareek
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Benkovic
        </surname>
        <given-names>
         SJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The purinosome: a case study for a mammalian metabolon
      </article-title>
      <source>
       Annu. Rev. Biochem.
      </source>
      <year>
       2022
      </year>
      <volume>
       91
      </volume>
      <fpage>
       89
      </fpage>
      <lpage>
       106
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XnvVOmurs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35320684
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9531488
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1325.47080
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kell
        </surname>
        <given-names>
         DB
        </given-names>
       </name>
       <name>
        <surname>
         Laubscher
        </surname>
        <given-names>
         GJ
        </given-names>
       </name>
       <name>
        <surname>
         Pretorius
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
      </article-title>
      <source>
       Biochem. J.
      </source>
      <year>
       2022
      </year>
      <volume>
       479
      </volume>
      <fpage>
       537
      </fpage>
      <lpage>
       559
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1ert7vK
      </pub-id>
      <pub-id pub-id-type="pmid">
       35195253
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Charnley
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13.3387C
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhsFCksrvP
      </pub-id>
      <pub-id pub-id-type="pmid">
       35697699
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9189797
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0063.00788
      </pub-id>
      <elocation-id>
       3387
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="other">
      Aschman, T. et al. Post-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal muscles.
      <italic>
       acta neuropathol commun.
      </italic>
      <bold>
       11
      </bold>
      , 193 (2023).
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nakahira
        </surname>
        <given-names>
         K
        </given-names>
       </name>
       <name>
        <surname>
         Hisata
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Choi
        </surname>
        <given-names>
         AMK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The roles of mitochondrial damage-associated molecular patterns in diseases
      </article-title>
      <source>
       Antioxid. Redox Signal.
      </source>
      <year>
       2015
      </year>
      <volume>
       23
      </volume>
      <fpage>
       1329
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2MXitVentLnJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       26067258
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4685486
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1357.33006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Grazioli
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Pugin
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Mitochondrial damage-associated molecular patterns: from inflammatory signaling to human diseases
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2018
      </year>
      <volume>
       9
      </volume>
      <fpage>
       1
      </fpage>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Frere
        </surname>
        <given-names>
         JJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery
      </article-title>
      <source>
       Sci. Transl. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       14
      </volume>
      <fpage>
       eabq3059
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xis1Sktb7L
      </pub-id>
      <pub-id pub-id-type="pmid">
       35857629
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Littlefield
        </surname>
        <given-names>
         KM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2
      </article-title>
      <source>
       PLoS Pathog.
      </source>
      <year>
       2022
      </year>
      <volume>
       18
      </volume>
      <fpage>
       e1010359
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhsFaqsbfP
      </pub-id>
      <pub-id pub-id-type="pmid">
       35617421
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9176759
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       07950199
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Iwasaki
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Putrino
        </surname>
        <given-names>
         D
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Why we need a deeper understanding of the pathophysiology of long COVID
      </article-title>
      <source>
       Lancet Infect. Dis.
      </source>
      <year>
       2023
      </year>
      <volume>
       23
      </volume>
      <fpage>
       393
      </fpage>
      <lpage>
       395
      </lpage>
      <pub-id pub-id-type="pmid">
       36967698
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9928485
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0734.05017
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         de Boer
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Decreased fatty acid oxidation and altered lactate production during exercise in patients with post-acute COVID-19 syndrome
      </article-title>
      <source>
       Am. J. Respir. Crit. Care Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       205
      </volume>
      <fpage>
       126
      </fpage>
      <lpage>
       129
      </lpage>
      <pub-id pub-id-type="pmid">
       34665688
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Colosio
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Structural and functional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection
      </article-title>
      <source>
       J. Appl. Physiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       135
      </volume>
      <fpage>
       902
      </fpage>
      <lpage>
       917
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2023amp..book.....C
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXit1SisL%2FM
      </pub-id>
      <pub-id pub-id-type="pmid">
       37675472
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       58.0155.02
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Posthuma
        </surname>
        <given-names>
         JJ
        </given-names>
       </name>
       <name>
        <surname>
         van der Meijden
        </surname>
        <given-names>
         PEJ
        </given-names>
       </name>
       <name>
        <surname>
         ten Cate
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Spronk
        </surname>
        <given-names>
         HMH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Short- and long-term exercise induced alterations in haemostasis: a review of the literature
      </article-title>
      <source>
       Blood Rev.
      </source>
      <year>
       2015
      </year>
      <volume>
       29
      </volume>
      <fpage>
       171
      </fpage>
      <lpage>
       178
      </lpage>
      <pub-id pub-id-type="pmid">
       25467962
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Charfeddine
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study
      </article-title>
      <source>
       Front. Cardiovasc. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       8
      </volume>
      <fpage>
       745758
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtVClsL%2FO
      </pub-id>
      <pub-id pub-id-type="pmid">
       34917659
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8670225
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Turner
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Long COVID: pathophysiological factors and abnormalities of coagulation
      </article-title>
      <source>
       Trends Endocrinol. Metab.
      </source>
      <year>
       2023
      </year>
      <volume>
       34
      </volume>
      <fpage>
       321
      </fpage>
      <lpage>
       344
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXmvVSjtL4%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       37080828
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10113134
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1509.01066
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Swank
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae
      </article-title>
      <source>
       Clin. Infect. Dis.
      </source>
      <year>
       2023
      </year>
      <volume>
       76
      </volume>
      <fpage>
       e487
      </fpage>
      <lpage>
       e490
      </lpage>
      <pub-id pub-id-type="pmid">
       36052466
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Aschman
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died
      </article-title>
      <source>
       JAMA Neurol.
      </source>
      <year>
       2021
      </year>
      <volume>
       78
      </volume>
      <fpage>
       948
      </fpage>
      <lpage>
       960
      </lpage>
      <pub-id pub-id-type="pmid">
       34115106
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1443.00009
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mageriu
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Zurac
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Bastian
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <name>
        <surname>
         Staniceanu
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Manole
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Histological findings in skeletal muscle of SARS-CoV2 infected patient
      </article-title>
      <source>
       J. Immunoass. Immunochem.
      </source>
      <year>
       2020
      </year>
      <volume>
       41
      </volume>
      <fpage>
       1000
      </fpage>
      <lpage>
       1009
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXis1yhurfM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Patterson
        </surname>
        <given-names>
         BK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <fpage>
       5526
      </fpage>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1388.35151
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Buonsenso
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies
      </article-title>
      <source>
       Lancet Microbe
      </source>
      <year>
       2023
      </year>
      <volume>
       4
      </volume>
      <fpage>
       e745
      </fpage>
      <lpage>
       e756
      </lpage>
      <pub-id pub-id-type="pmid">
       37385286
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Appelman
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination
      </article-title>
      <source>
       EBioMedicine
      </source>
      <year>
       2021
      </year>
      <volume>
       72
      </volume>
      <fpage>
       103561
      </fpage>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1520.90171
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2021
      </year>
      <volume>
       595
      </volume>
      <fpage>
       426
      </fpage>
      <lpage>
       431
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021Natur.595..426W
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhsFSnsbvK
      </pub-id>
      <pub-id pub-id-type="pmid">
       34126625
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8277577
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1358.90069
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gallais
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
      </article-title>
      <source>
       EBioMedicine
      </source>
      <year>
       2021
      </year>
      <volume>
       71
      </volume>
      <fpage>
       103561
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhvFWitL%2FJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       34455390
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8390300
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1549.74519
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hendrickse
        </surname>
        <given-names>
         PW
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Capillary rarefaction during bed rest is proportionally less than fibre atrophy and loss of oxidative capacity
      </article-title>
      <source>
       J. Cachexia Sarcopenia Muscle
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       2712
      </fpage>
      <lpage>
       2723
      </lpage>
      <pub-id pub-id-type="pmid">
       36102002
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9745458
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1367.93466
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agergaard
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Myopathy as a cause of Long COVID fatigue: evidence from quantitative and single fiber EMG and muscle histopathology
      </article-title>
      <source>
       Clin. Neurophysiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       148
      </volume>
      <fpage>
       65
      </fpage>
      <lpage>
       75
      </lpage>
      <pub-id pub-id-type="pmid">
       36804609
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Pizzuto
        </surname>
        <given-names>
         DA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Lung perfusion assessment in children with long-COVID: a pilot study
      </article-title>
      <source>
       Pediatr. Pulmonol.
      </source>
      <year>
       2023
      </year>
      <volume>
       58
      </volume>
      <fpage>
       2059
      </fpage>
      <lpage>
       2067
      </lpage>
      <pub-id pub-id-type="pmid">
       37097045
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1437.91309
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cotler
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Holtzman
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Dudun
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Jason
        </surname>
        <given-names>
         LA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A brief questionnaire to assess post-exertional malaise
      </article-title>
      <source>
       Diagnostics
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       66
      </fpage>
      <pub-id pub-id-type="pmid">
       30208578
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6165517
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Krupp
        </surname>
        <given-names>
         LB
        </given-names>
       </name>
       <name>
        <surname>
         Alvarez
        </surname>
        <given-names>
         LA
        </given-names>
       </name>
       <name>
        <surname>
         Larocca
        </surname>
        <given-names>
         NG
        </given-names>
       </name>
       <name>
        <surname>
         Scheinberg
        </surname>
        <given-names>
         LC
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fatigue in multiple sclerosis
      </article-title>
      <source>
       Arch. Neurol.
      </source>
      <year>
       1988
      </year>
      <volume>
       45
      </volume>
      <fpage>
       435
      </fpage>
      <lpage>
       437
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaL1c7ot1yqtw%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       3355400
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0651.60049
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Smets
        </surname>
        <given-names>
         EMA
        </given-names>
       </name>
       <name>
        <surname>
         Garssen
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Bonke
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         De Haes
        </surname>
        <given-names>
         JCJM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue
      </article-title>
      <source>
       J. Psychosom. Res.
      </source>
      <year>
       1995
      </year>
      <volume>
       39
      </volume>
      <fpage>
       315
      </fpage>
      <lpage>
       325
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK2MzmtlOgsQ%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       7636775
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Clevenger
        </surname>
        <given-names>
         KA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effect of sampling rate on acceleration and counts of hip- and wrist-worn ActiGraph accelerometers in children
      </article-title>
      <source>
       Physiol. Meas.
      </source>
      <year>
       2019
      </year>
      <volume>
       40
      </volume>
      <fpage>
       095008
      </fpage>
      <pub-id pub-id-type="pmid">
       31518999
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1476.83197
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="other">
      Gnaiger E. (2020) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 5th ed. Bioenerg Commun 2:112 (2020).
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gnaiger
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology
      </article-title>
      <source>
       Int. J. Biochem. Cell Biol.
      </source>
      <year>
       2009
      </year>
      <volume>
       41
      </volume>
      <fpage>
       1837
      </fpage>
      <lpage>
       1845
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1MXhtVentbvI
      </pub-id>
      <pub-id pub-id-type="pmid">
       19467914
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0126.23603
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Gnaiger
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Mitochondrial coupling and capacity of oxidative phosphorylation in skeletal muscle of Inuit and Caucasians in the arctic winter
      </article-title>
      <source>
       Scand. J. Med. Sci. Sports
      </source>
      <year>
       2015
      </year>
      <volume>
       25
      </volume>
      <fpage>
       126
      </fpage>
      <lpage>
       134
      </lpage>
      <pub-id pub-id-type="pmid">
       26589126
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Horwath
        </surname>
        <given-names>
         O
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Variability in vastus lateralis fiber type distribution, fiber size, and myonuclear content along and between the legs
      </article-title>
      <source>
       J. Appl. Physiol.
      </source>
      <year>
       2021
      </year>
      <volume>
       131
      </volume>
      <fpage>
       158
      </fpage>
      <lpage>
       173
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhs1Cju77I
      </pub-id>
      <pub-id pub-id-type="pmid">
       34013752
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0949.35060
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wüst
        </surname>
        <given-names>
         RCI
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Region-specific adaptations in determinants of rat skeletal muscle oxygenation to chronic hypoxia
      </article-title>
      <source>
       Am. J. Physiol. Heart Circ. Physiol.
      </source>
      <year>
       2009
      </year>
      <volume>
       297
      </volume>
      <fpage>
       H364
      </fpage>
      <lpage>
       74
      </lpage>
      <pub-id pub-id-type="pmid">
       19429822
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0274.47008
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Van Der Zwaard
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Critical determinants of combined sprint and endurance performance: an integrative analysis from muscle fiber to the human body
      </article-title>
      <source>
       FASEB J.
      </source>
      <year>
       2018
      </year>
      <volume>
       32
      </volume>
      <fpage>
       2110
      </fpage>
      <lpage>
       2123
      </lpage>
      <pub-id pub-id-type="pmid">
       29217665
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1428.94028
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Grootemaat
        </surname>
        <given-names>
         AE
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Lipid and nucleocapsid N-protein accumulation in COVID-19 patient lung and infected cells
      </article-title>
      <source>
       Microbiol. Spectr.
      </source>
      <year>
       2022
      </year>
      <volume>
       10
      </volume>
      <fpage>
       e0127121
      </fpage>
      <pub-id pub-id-type="pmid">
       35171025
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Schomakers
        </surname>
        <given-names>
         BV
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Polar metabolomics in human muscle biopsies using a liquid–liquid extraction and full-scan LC–MS
      </article-title>
      <source>
       STAR Protoc.
      </source>
      <year>
       2022
      </year>
      <volume>
       3
      </volume>
      <fpage>
       101302
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xhs1SnsrrE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35479116
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9035783
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1505.93274
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="other">
      Daimon, T. Box–Cox transformation.
      <italic>
       Int. Encycl. Stat. Sci.
      </italic>
      <bold>
       1
      </bold>
      , 176–1781 (2011).
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Diedenhofen
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Musch
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       cocor: a comprehensive solution for the statistical comparison of correlations
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2015
      </year>
      <volume>
       10
      </volume>
      <fpage>
       e0121945
      </fpage>
      <pub-id pub-id-type="pmid">
       25835001
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4383486
      </pub-id>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0949.65050
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Searle
        </surname>
        <given-names>
         SR
        </given-names>
       </name>
       <name>
        <surname>
         Speed
        </surname>
        <given-names>
         FM
        </given-names>
       </name>
       <name>
        <surname>
         Milliken
        </surname>
        <given-names>
         GA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Estimated marginal means, aka least-squares means [R package emmeans version 1.8.5]
      </article-title>
      <source>
       Am. Stat.
      </source>
      <year>
       2023
      </year>
      <volume>
       34
      </volume>
      <fpage>
       216
      </fpage>
      <lpage>
       221
      </lpage>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       0468.62066
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hedges
        </surname>
        <given-names>
         LV
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Distribution Theory for Glass’s estimator of effect size and related estimators
      </article-title>
      <source>
       J. Educ. Stat.
      </source>
      <year>
       1981
      </year>
      <volume>
       6
      </volume>
      <fpage>
       107
      </fpage>
      <lpage>
       128
      </lpage>
      <pub-id assigning-authority="Zentralblatt MATH" pub-id-type="other">
       1380.65111
      </pub-id>
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec30">
     <title>
      Taarifa za ziada
     </title>
     <p id="Par45">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44432_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Data File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44432_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44432_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec31">
     <title>
      Data ya chanzo
     </title>
     <p id="Par46">
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44432_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Taarifa za ziada
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-023-44432-3">
     https://doi.org/10.1038/s41467-023-44432-3
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
